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The course of Multiple Sclerosis (MS), a chronic autoimmune disease, can be 
influenced by systemic infections. The common notion is that bacterial infections worsen 
disease symptoms and lead to enhanced neurodegeneration. However, the underlying 
biological mechanisms by which bacterial infections may lead to neurodegeneration in 
MS are complex and poorly understood. Here, we assessed the disease-modulating 
effect of an acute Escherichia coli and a chronic Staphylococcus aureus infection on the 
clinical course and the extent of neurodegeneration in experimental autoimmune 
encephalomyelitis (EAE), an animal model of MS. 
In this study, we did not observe any disease modulating effect of acute E. coli 
infection on EAE when infection was induced in both the preclinical and in the clinical 
phase of the disease. However, we observed that local application of S. aureus in the 
preclinical phase of the disease induced a chronic systemic inflammatory response with 
increased in T- and B-cell counts as well as systemic production of pro-inflammatory 
cytokines. Unexpectedly, the infection with S. aureus completely prevented the 
development of clinical EAE. Moreover, it markedly decreased the extent of 
inflammatory infiltrates and demyelination of the optic nerve and increased the number 
of surviving retinal neurons. Using a S. aureus strain deficient for the extracellular 
adherence protein (Eap) we identified this protein to be at least partly responsible for 
the inhibitory effect of S. aureus infection on autoimmune inflammation of the central 
nervous system. Thus our results show for the first time a beneficial effect of a chronic 
bacterial infection on neurodegeneration in EAE and open the avenue for the design of 
new neuroprotective therapy in MS. 




1.1: Multiple sclerosis: General background  
Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating disease of the 
central nervous system (CNS), which often manifests with optic neuritis (Hickman et al., 
2002). MS was first described in detail by Dr. Jean-Martin Charcot in 1866 and called it 
as “sclerose en plaques” (Compston, A. 1998). The main target of damage in MS is the 
myelin sheaths which are wrapped around the neurons and make efficient conduction of 
nerve impulse. During the disease course, there is a destruction of the myelin sheath 
which may lead to the impairment of impulse along the axons which further cause 
neurological abnormalities and typically affect motor, sensory and visual functions 
(Compston and Coles, 2008). 
It is estimated that about 2.3 million people are affected by MS and the number 
of patients are increasing over the time (MS Atlas 2013). MS is present worldwide, but 
the prevalence of MS varies in different parts of the world. Earlier studies have indicated 
that the incidence of the disease increased with the distance from the equator (Kurtzke, 
2005; Miller et al., 1990; Simpson et al., 2011). The highest prevalence of MS is seen in 
people from North America and Europe (>100/100 000) and it is rare amongst Asian 
and African (2/100 000) (MS Atlas 2013). However, the prevalence of MS also varies 
considerably within regions (Compston and Coles, 2008).  
MS is the most common neurological disease of young adults and females are 
twice more affected than males (Alonso and Hernan, 2008; Rezaali et al., 2013). 
Although with lower incidence rate of MS in male, they show slower recovery and show 
more aggressive nature of the disease course than females (Koutsis et al., 2010; 
Leibowitz and Alter, 1970; Runmarker and Andersen, 1993; Weinshenker et al., 1991). 
Due to early onset, the disease has a huge impact on the socioeconomic status of an 
individual. The majority of MS patients are diagnosed between the age of 20 and 50 
years (National MS society). The first clinical symptoms can include fatigue, headache, 
limb weakness, vision abnormalities, impairment of bladder, depression and problems 
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with balance and coordination (Schneider, 2005). Clinical onset of disease is 
characterized by the neurological relapses followed by remission and this type of 
disease is referred as relapsing-remitting type of MS (RRMS) and found amongst 80 - 
85% of MS patients (Gold et al., 2010; Rovaris et al., 2006). RRMS patients are 
clinically stable between the relapse for several years. However, there is an increasing 
evidence to suggest that the axonal and neuronal loss occurs in the early phase of MS 
(Kornek and Lassmann, 1999; Trapp et al., 1998; Trapp et al., 1999). The majority of 
RRMS patients further develop secondary progressive MS, (SPMS) where patients 
show axonal loss and neurological deficit without relapses (Fitzner and Simons, 2010; 
Rovaris et al., 2006). This could lead permanent cause of neurological disability of MS 
patients. Approximately 10-15% of patients has no remitting phase and show 
progressive worsening of the disease from the start and called as primary progressive 
MS, (PPMS) (Andersson et al., 1999; Miller and Leary, 2007). Recent advances in 
magnetic resonance imaging techniques improved all over the world which added the 
value in the diagnosis of MS patient by characterizing the lesions size and locations 
directly into the white matter of the brain in very early stage of disease (Patsopoulos et 
al., 2011). Interferon-beta (IFN-β), glatiramer acetate (GA), and natlizumab, are some 
common medication used for the treatment of MS. Since 2010 fingolimod (FTY 720) 
was approved for the treatment of MS as a first oral drug. These drugs slow down the 
progression of disease, but they could not prevent the neuronal cell loss and in the 
consequences of this ongoing progression of neuronal loss patients develop the long 
term disability. Therefore there is a need to design of new neuro-protective therapy in 
MS.  
1.2: Pathogenesis and pathology 
MS predominantly assumed to be a T-cell mediated autoimmune disease (Wekerle, 
2008) involving both CD4+ T helper-cell and CD8+ T cytotoxic-cell (McFarland and 
Martin, 2007). In the recent years the role of B-cells is also emphasized in MS 
pathogenesis (Hirotani et al., 2010). Although the sequential event taking place in the 
pathogenesis of MS is hardly known, but activation of auto reactive T-cells is supposed 
to be the initial step in the disease pathogenesis (Markovic-Plese et al., 2004). 
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However, factors which trigger this phenomenon are not exactly known. From several 
clinical studies myelin reactive T-cells has been shown to be present in every individual. 
But these myelin-reactive T-cells, reactive to myelin basic protein (MBP), were found to 
be significantly higher in MS patients compared to healthy controls (Zhang et al., 1994). 
Thus it is presumed that some environmental factors, especially the microbial antigens, 
which probably supposed to cross-activate T-cells specific for myelin epitopes through a 
mechanism called molecular mimicry in susceptible individuals (Wucherpfennig and 
Strominger, 1995). During the activation cascade T-cell receptor present on T-cell 
recognizes and binds to the myelin specific antigen present on major histocompatibility 
complex (MHC) of an antigen-presenting cell (APC) which delivers co-stimulatory signal 
leading to activation of myelin specific T-cells (Fig 1.1). These activated T-cells cross 
the blood-brain barrier (BBB), a physical barrier formed by the endothelial cells that form 
the walls of the capillaries, and enter into the CNS. 
The BBB maintains highly controlled microenvironment of the CNS by regulating 
several functions across the CNS like passive diffusion of nutrition, maintenance ionic 
balance, prevention of macromolecules and neurotoxins to enter into the CNS.  During 
several neurological disorders and in traumatic brain injury the BBB is breached, which 
allows the inflammatory cells to enter into the CNS and impair the neuronal function 
(Rosenberg, 2012). The interactions between the adhesion- and signaling-molecules 
present on leukocyte and endothelial cells lining the BBB leads to the recruitment of 
pro-inflammatory cells to the CNS (Rossi et al., 2011). That includes the involvement of 
cytokines, chemokines and adhesion molecules expressed by both the activated 
endothelium and the immune cells, which especially involve the very late antigen-4 - 
Vascular cell adhesion molecule-1 (VLA-4 - VCAM-1) and the lymphocyte function-
associated antigen-1-intercellular adhesion molecule-1 (LFA-1 - ICAM-1) adhesion 
systems (Xie et al., 2006). Monoclonal antibody like natalizumab is in therapeutic use 
for MS, which targets interaction between VLA-4 - VCAM-1, and subsequently block the 
migration of activated T-cells across the BBB and reduces the severity of disease. 
Although of a majority of T-cells are crossing the BBB primarily through VLA-4 - VCAM-
1 adhesion pathway, but the LFA-1 - ICAM-1 also plays an important role in 
downstream to this pathway. 




Fig 1.1: Immunopathogenesis of MS: Initial activation of T-cells takes place in the periphery 
by antigen presenting cells (APCs) followed by transendothelial migration of activated T-cells 
across the blood-brain barrier by use of different adhesion system. After crossing the BBB these 
cells undergo reactivation within the CNS and induce the release of several pro-inflammatory 
cytokines, which further cause damage to the BBB. The damaged BBB allows the other blood 
cells to enter into the CNS. That together with other brain cells contribute to the damage of the 
myelin sheath and ultimately to the death of the neuronal cell bodies. 
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It has been also suggested that, the integrity of the BBB could be protected by blocking 
the infiltration of inflammatory cell recruitment secondary to the activated T-cells (Xie et 
al., 2006). Several studies indicated the role of ICAM in pathogenesis of MS (Bullard et 
al., 2007; Steiner et al., 2010). Eventually there is no current therapy targeting the LFA-
1 - ICAM-1 adhesion pathway. However, some microbial products like extracellular 
adhesion protein (Eap), secreted from staphylococcus aureus (S. aureus) have been 
shown to have potential which specifically targeted LFA-1 - ICAM-1 but not VLA-4 - 
VCAM-1 mediated T-cell recruitment at the BBB in an animal model of MS (Xie et al., 
2006).  
After crossing the BBB, T-cells get reactivated by antigen presented on resident 
brain antigen presenting cells (APCs), which triggers the release of pro-inflammatory 
cytokines (Th1 cytokine profile) like Interleukin (IL)-1, IL-2, IL-6, IL-12, IFN-gamma and 
TNF-α that further disrupt the BBB and resulting in a massive infiltration of other 
inflammatory cells from the peripheral blood circulation. The inflammatory cells further 
destroy the myelin sheath of the neurons and subsequently cause neurodegeneration 
and plaque formation in the CNS (Fig 1.1). 
Since multiple sclerosis is clinically, genetically and pathologically heterogeneous 
disease, one can assume that more than one pathogenic mechanism leading to the 
disease progression. It has been shown that axonal injury and neuronal cell loss occurs 
in the early phase of MS lesion formation and is most pronounced in active 
demyelinating phase of the disease (Kuhlmann et al., 2002). This slow and continuous 
axonal destruction may account more to the global axonal loss in MS. 
A pathological hallmark of MS is multiple focal areas of myelin loss called 
plaques, especially in the white matter of the CNS (Ge, Y. 2006). Inflammation, 
demyelination, oligodendrocyte injury, astrogliosis, neurodegeneration and axonal loss 
are the main factors associated with the plaque formation. MS plaques, may develop 
anywhere in the CNS, but most frequently affected areas are the optic nerves, spinal 
cord, brainstem, peri-ventricular white matter regions and cerebellum (Popescu and 
Lucchinetti, 2012). Plaques can be in acute or in chronic form that depends on the 
degree of inflammation present within the plaques. Acute plaques are more common in 
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patient with RRMS, which shows robust inflammatory infiltration with lymphocytes 
(predominantly T-cell) macrophages and distributed throughout the lesions and shows 
parenchymal edema (Frohman et al., 2006) that can be detected by gadolinium 
enhancement on MRI. Moreover, these plaques also contain a considerable number of 
oligodendrocyte precursor cells, which probably help the CNS in the restoration of 
myelin (Wolswijk, 1998). 
Once the inflammation in the acute plaque resolves in the brain or spinal cord it 
forms scars and turned into a chronic form of plaque and accumulates throughout the 
disease course. Chronic plaques are more common in patients with progressive MS 
(Kutzelnigg and Lassmann, 2005). These plaques show complete demyelination, 
substantial loss of oligodendrocytes and axons, astrogliosis and less infiltration of 
lymphocytes and macrophages (Popescu and Lucchinetti, 2012). 
1.3: Genetics and role of infection 
The exact cause of this highly complex disease is still unknown. It has been suggested 
that both genetic and environmental factors are the two major determinants which 
contribute to the disease susceptibility. However, the precise impact of these factors is 
not very clear so far and that can be either harmful or protective. 
Demographic studies and data from the epidemiology suggest a strong influence 
of genetic factors in pathogenesis of MS (Barcellos et al., 2006; Chataway et al., 2001; 
Dyment et al., 1997; Sawcer et al., 2011; Weinshenker, 1994). Human leukocyte 
antigen (HLA) locus, present on the short arm of chromosome 6, in major 
histocompatibility complex (MHC) region was discovered as a first potential genetic risk 
factor associated with the pathogenesis of MS in 1970s (Munoz-Culla et al., 2013). 
These genes encode the cell surface glycoproteins, which are the key components of 
the immune system. Since 1970s a great deal of effort has been made to understand 
the functional and mechanistic role of the genes present in this locus (McElroy and 
Oksenberg, 2011). From a collaborative effort of Wellcome Trust Case Control 
Consortium 2 and International Multiple Sclerosis Genetics Consortium, containing large 
data set, it has been shown that HLA DRB1*15: 01 loci have the strongest association 
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with multiple sclerosis and also identified 29 novel susceptibility loci (Sawcer et al., 
2011). Even though with the strong genetic evidences it is also noticed that in 75% of 
the population only one sibling getting affected with MS which signifies the role of 
additional factors which play an important role in the pathogenesis of MS (Ebers et al., 
1986; Sadovnick, 1993; Sadovnick et al., 2009). 
The idea of MS pathogenesis and the role of infection came in late 1800s by 
Pierre Marie, and since then a number of different pathogens have been associated and 
then discarded due to lack of evidences. Many clinical studies have shown that common 
bacterial and viral infections that cause respiratory infections and urinary tract infections 
may alter the immune status of an individual. However, in regards to MS and its animal 
model, it is observed previously that infections with these bacteria and viruses 
significantly influence the course and severity of MS and experimental autoimmune 
encephalomyelitis (EAE) especially immediately after viral and bacterial infections 
(Tauber et al., 2007). 
Epstein Barr virus (EBV) infection is most promising candidates, which are 
gaining support for being involved in MS pathogenesis. The link between EBV and MS 
was come in picture from a study of Warner and Carp in 1981, who suggested that the 
young adults are at highest risk of acquiring MS where the chances of infectious 
mononucleosis are at most (Warner and Carp, 1981). EBV infection occurs in over 90% 
of the general population, but in an epidemiological study conducted in the past 30 
years revealed that MS patients are almost universally, seropositive for EBV infection 
(Pender, 2011). Antibodies against EBV antigens particularly, Epstein-Barr nuclear 
antigen-1 was detected in the cerebrospinal fluid (CSF) of the MS patients in 
significantly higher amount compared to the control (13% of controls against 85% of MS 
patients, p<0.001) (Bray et al., 1992; Cepok et al., 2005; Jaquiery et al., 2010; Rand et 
al., 2000). There are several other viral studies which are linked to the etiology of MS 
like human herpesvirus-6 (Challoner et al., 1995; Kim et al., 2000; Opsahl and Kennedy, 
2005; Panitch, 1994), adenoviruses (Andersen et al., 1993), picornavirus (Kriesel et al., 
2004), varicella-zoster virus (Mancuso et al., 2007; Ordonez et al., 2004) and torque 
teno virus (Sospedra et al., 2005).  
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Even though viral particle can cause the infection of the brain directly, but in most of the 
studies researchers could not found presence of viral particle in the brain. Moreover, 
several patients have been documented until now and they were sero-negative for 
these viruses. Hence these results suggest that these viruses are the strong risk factors 
for the pathogenesis of MS rather than a direct cause for acquiring this disease. 
Earlier studies with bacterial infection and MS were not given importance due to 
development of thrust (Sibley and Foley, 1965). However, in recent time, studies with 
the animal model and MS patient shows that bacterial infection may lead to 
exacerbations in MS (Buljevac et al., 2002; Herrmann et al., 2006). The possible 
explanation for these exacerbations is that, an infection may increase the inflammatory 
activity in the peripheral vascular system which may lead to more sustained 
neurological damage over a period of time. Thus these bacterial components appear to 
play an important role in MS pathogenesis and were found also in the CNS of MS 
patients (Schrijver et al., 2001). In a study by Sriram and colleagues in 1999, it was 
observed that 97% of CFS samples from MS patients were found positive for Chlamydia 
pneumoniae (C. pneumoniae) major outer membrane protein gene against 18% of 
control. Moreover, from the culture of the CSF they showed the presence of C. 
pneumoniae in 64% of the MS patients against 11% from control patients. In contrast, 
some bacterial component seems to prevent the EAE (Ben-Nun et al., 1995; Ben-Nun 
and Yossefi, 1992). 
In the last few decades with the increase in the sanitary condition in western 
countries showed a tremendous increase in the incidence of many immune disorders 
including MS (Bach, 2005). Epidemiological evidence indicates a strong correlation 
between improved sanitation and an increase in the number of patients with such 
immune disorders (Fig 1.2) (Bach, 2002; Christen and von Herrath, 2005). Hence this 
increase in the immune disorder against high sanitation level gives rise to new 
hypothesis known a hygiene hypothesis, first proposed by Strachan for allergic 
disorders (Strachan, 1989) and now correlates well with several other autoimmune 
disorders. According to the hygiene hypothesis, the children grows in the highly hygienic 
environments have negative effect on their immune development which may lead to an 
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in the incidence of autoimmune disorders like MS (Fleming and Cook, 2006; Leibowitz 
et al., 1966). This finding also supported by migration studies which indicate that moving 
from a high- to a low-risk area in childhood reduces the risk of MS, while moving during 
late adulthood has no impact on susceptibility of MS. Migration in the opposite direction, 
does not seems to increase the MS risk substantially until the next generation (Ascherio 
and Munger, 2007; Gale and Martyn, 1995; McLeod et al., 2012; Orton et al., 2010). 
 
Fig 1.2: Infectious disease and autoimmune disorder: Epidemiological data indicate an 
inverse relation between the Incidence Infectious Diseases (A) and the Incidence of Immune 
Disorders (B) from 1950 to 2000 (Bach, 2002).  
These data suggest that an environmental factor, like infection in childhood is 
important, to determine MS risk. The possible mechanism behind this protection might 
be that, infection may shift the immunological balance toward a more immune-
suppressed state or infection may cause hyper activation of auto reactive cells which 
possibly lead to clonal deletion and ultimately reduces the number of aggressive cells. 
Recent epidemiological investigations with Trichuris trichiura, a common human 
pathogen, indicate that MS prevalence appears to fall sharply once a critical threshold 
of Trichuris trichiura is exceeded (Fleming and Cook, 2006). These studies in humans 
are validated by investigating the impact of some other parasites in animal models of 
MS. In one such study animals were pre-infected with the ova of Schistosoma mansoni 
which results in either attenuation or delayed onset of EAE (La Flamme et al., 2003). 
Studies also indicate that the infection with the ova of Schistosoma mansoni 
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significantly down regulates the induction of some pro-inflammatory cytokine such as IL-
12, TNF-alpha (TNF-α), IFN-gamma and express more anti-inflammatory cytokine like 
IL-10 and TGF-beta. Moreover, these studies also indicate the role of regulatory T- and 
B-cells in the disease onset. Although lots of research are ongoing on the parasitic 
infection and viral infection to their relation to the autoimmune diseases like MS, but 
eventually the role of bacterial infection and their relation to the MS still need to be 
explored. 
1.4: Diagnosis and therapy  
A careful medical history and a thorough neurological examination form the basis for 
treatment of MS patients. There are some defined criteria made in the diagnosis of MS 
which is changed and modified over time. First diagnostic criteria used for MS was 
proposed by Schumacher in 1956 (Ross et al., 1965) which were updated by Poser 
criteria in early 1980s. Poser criteria first emphasized the use of MRI for diagnosis of 
MS patient. This criteria also included the analysis of cerebro-spinal fluid analysis (CSF) 
examination (Poser et al., 1983). The poser criteria was used for several years and 
updated by “McDonald Criteria” in 2001 (McDonald et al., 2001) and revised time to 
time. The latest revision of McDonald criteria was made in 2010 by (Polman et al., 
2011). According to the latest revision of this criteria if a patient has had more than two 
attacks, or having more than two lesions, or one lesion but with sufficient evidence of a 
prior attack, can be diagnosed, if the patient does not fulfill these criteria the further 
attack is needed for the secure diagnosis (Polman et al., 2011). The McDonald criteria 
make use of advancement in MRI techniques which allows the diagnosis to be accurate 
at earlier stage of disease, and therefore offer the potential for earlier treatment. The 
expanded disability status scale (EDSS) is used worldwide in clinics to evaluate the 
disease progression in MS, where higher EDSS scores indicate more disability. Since 
2001 McDonald criteria made the foundation to diagnose MS in most of the countries. 
Over the last 20 year, several therapeutic agents have been studied and tested 
for the MS treatment. However, immune suppressive therapy becomes the first choice 
for the attenuation the disease progression probably due to inflammatory nature of this 
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disease. The first line treatment consists of interferon-β, which is either IFNβ-1a or 
IFNβ-1b and glatiramer acetate (GA) for the RRMS.  
IFN-β treatment is administered sub-cutaneousaly showed a reduction in the relapse 
rate by 30% and reduce lesion load (Jacobs et al., 1996; Jacobs et al., 1995). Although 
the exact mechanism of action is not clearly understood until now, but it was suggested 
from several studies that INF-β therapy reduces the expression of MHC class II on 
APCs, reduces proliferation of T-lymphocytes and the production of anti-inflammatory 
cytokines (Dhib-Jalbut and Marks, 2010; Genc et al., 1997; Jiang et al., 1995; 
Teleshova et al., 2000), increases cytotoxic T-lymphocyte and Fas surface molecule on 
CD4+ cells and promote apoptosis of aggressive cells (Hallal-Longo et al., 2007). Other 
disease modifying drugs heavily in use is glatiramer acetate (GA), a four-amino acid 
synthetic copolymer administered sub-cutaneoualy and have been shown to reduce the 
relapse rate by 29% (Johnson et al., 1995). The precise mechanism of action of GA is 
not clearly known, but several studies indicate that GA leads to an inhibition of the 
antigen- specific T- lymphocyte activation by binds directly to the portion of the APC. 
Due to lower efficacy of these drugs, escalation therapy for the treatment MS was 
introduced which primarily includes natalizumab (humanized monoclonal antibody) and 
fingolimod (sphingosine-1 phosphate receptor agonist). Natalizumab targets a 
component of the VLA-4, a4-integrin molecule which is present on lymphocytes thus 
prevent the interaction with VCAM-1 found on endothelial surfaces and subsequently 
blocks the infiltration of these lymphocytes across the BBB which results in reduced 
inflammation of the CNS. Due to a very high efficacy (Miller et al., 2007; Polman et al., 
2006) and severe side effect of natalizumab (Bloomgren et al., 2012; Clifford et al., 
2010), several other monoclonal antibody directed therapy (Alemtuzumab, 
Ocrelizumab) is under trial for MS treatment. A sphingosine-1 phosphate receptor 
agonist, Fingolimod (FTY720), which blocks leukocyte trafficking in lymph nodes, is the 
first oral disease-modifying treatment available for relapsing MS and reduces the 
relapse rate by 54% and shows a significant decline in MRI lesion (Kappos et al., 2010). 
Mitoxantrone an anthracenedione cytotoxic agent can cross the disrupted BBB and 
inhibits DNA replication and reduces lymphocyte proliferation. Although mitoxantrone is 
effective in MS treatment, it remains second line for RRMS due to serious adverse 
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effects. The role of B-cell has been explored in the MS and several therapies are on trial 
now a day’s targeting B-cell populations and such hypothesis leads to the development 
of Rituximab and Ocrelizumab (van Oers et al., 2010; Zhou et al., 2008).  
Although in the last few years there is a huge intensification of MS therapy and 
have shown very high efficacy, especially in the RR form of MS but none of the 
marketed anti-inflammatory therapies are approved for PPMS or SPMS (Cree, 2014). 
Moreover, there is no treatment option available, which makes the neurological 
impairment reversed. More studies are needed to develop therapies which could control 
neurodegeneration, which is the main cause of permanent neurological disability. 
1.5: Experimental autoimmune encephalomyelitis  
Since the CNS is hardly accessible in humans for molecular and biochemical studies, 
therefore to assess the impact of a treatment or infection on MS various animal models 
have been used so far. These experimental animal models have provided important 
information in our understanding of various human autoimmune diseases which allow 
us to investigate the influence environmental and genetic factors associated with the 
disease progression. These animal models also provide a different experimental 
therapeutic approach to test the impact of a particular drug before going to trial in 
human.  
Although none of the animal models replicates all the immunological and 
histopathological aspects of MS. However, experimental autoimmune encephalomyelitis 
(EAE) is one of the most commonly used models of MS (Wekerle et al., 1994) and 
shows several immunological and histopathological aspects of MS. EAE is an 
inflammatory autoimmune disease of CNS clinically manifested by the development of a 
tail and limb paralysis which reflect the histopathological resemblance to MS (Goverman 
et al., 1993; Swanborg, 1995). Depending on the strain of the animals an EAE can be 
induced in animals models by immunization with various myelin proteins like proteolipid 
protein (PLP), myelin oligodendrocyte glycoprotein and myelin basic protein (MBP) 
along with the adjuvants (Gold et al., 2006). The most commonly used adjuvant is 
Freund’s adjuvant which contains mineral oil together with heat killed Mycobacterium 
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tuberculosis. To induce EAE, pertussis toxin is also used in combination with myelin 
proteins several animal model. The EAE can also be induced by adoptive transfer of 
myelin specific activated T-cells (Baxter, 2007; Zamvil and Steinman, 1990). 
MOG is a myelin surface antigen, highly conserved between species (Gardinier 
et al., 1992; Kroepfl et al., 1996) and present on the outer lamella of the myelin sheath 
and is recognized by activated T-lymphocytes and demyelinating antibodies. The 
precise biological function of MOG is not known, although it has been speculated that it 
has an adhesive function between myelin sheets and provides microtubule stability in 
oligodendrocytes. Immunization with recombinant myelin oligodendrocyte glycoprotein 
leads to the activation of MOG specific T-cells, which further reaches to the secondary 
lymph nodes where these cells get proliferated and migrated to the CNS by crossing the 
BBB (Cannella et al., 1990).  Migration of these activated T-cells cause autoimmune 
inflammation of the CNS and release of pro-inflammatory cytokine which induces more 
damage to the BBB. The breakage of BBB allows other peripheral blood cells like B-
cells, monocytes and macrophages to enter into the CNS, which primarily attack the 
myelin sheath of neuron (Traugott et al., 1986). 
In this thesis dissertation, we have used MOG (extracellular domain of rat MOG 
amino acid sequence 1-125) immunized female Brown Norway (BN) rats as an animal 
model. After an active immunization with MOG this animal model shows severe optic 
neuritis with acute axonal degeneration of the optic nerve (ON) and consecutive 
apoptosis of retinal ganglion cells (RGCs) in more than 90% of the rat regardless of a 
clinical manifestation of the disease (Hobom et al., 2004; Maier et al., 2006; Meyer et 
al., 2001). Therefore, this EAE model provides a unique tool to investigate the 
morphological changes in neuronal cell bodies and in axons. 
1.6: Infection models 
Epidemiological studies suggest that MS is greatly influenced by environmental factors 
like infection. The role of viruses in MS etiology is highly convincing. Moreover, it is also 
shown that bacterial components like enterotoxins, LPS and peptidoglycans are able to 
influence the course of EAE (Moreno et al., 2011; Schiffenbauer et al., 1993; Soos et 
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al., 1995). But the role of common bacterial infections has hardly been explored which 
reflect the true clinical situation. Although in most studies, the effects of acute infection 
were examined, but in the best of my knowledge the impact of chronic bacterial infection 
was never been evaluated which more closely mimic the clinical situation in humans. 
Therefore in this thesis dissertation we evaluated the impact of both acute and chronic 
infections in MOG immunized female BN rat. 
1.6.1: Acute infection model 
Despite of strong stimulatory effect of S. aureus enterotoxins on human (Langford et al., 
1978; Peavy et al., 1970) and mouse (Janeway et al., 1989; White et al., 1989) T-
lymphocyte subsets, it was unable to stimulate proliferative responses of rat T-
lymphocytes in a dose dependent manner (Ben-Nun and Yossefi, 1992). The studies 
with these bacterial components induce different responses towards different animal 
models. Such studies cannot be correlated with the normal infectious condition in MS or 
EAE.  
Du and coworkers (2002) showed in mice that intraperitoneal infection with C. 
pneumoniae can aggravate symptoms of EAE. This effect is likely to occur, since 
infection of the CNS increases the auto-reactive lymphocyte pool, hence influenced the 
development of autoimmune disease. However, in the same study infection with 
Chlamydia trachomatis did not influence the clinical course of disease. This study 
indicates that a CNS infection would thus essential for a worsening of EAE and it is also 
likely possible that the impact of infection on EAE varies with infection with different 
microorganisms. Hermann and colleagues in 2006 did an experiment where they 
infected the animals with Streptococcus pneumoniae at different time point after 
immunization in EAE. They observed that infection was able to exacerbate EAE only in 
case when the infection was made on day 7 post immunization (early asymptomatic 
phase). However, they did not observe any influence of infection on EAE when infection 
was made on 2 days prior to immunization or during the late phase of the disease (day 
21 pi). This study not only indicates the influences of infection on EAE rather the 
importance of infection induced at different time points during the course of the disease 
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are equally important. Furthermore, they also observed that bacterial infection enhances 
the release of pro-inflammatory cytokines in peripheral blood circulation. As indicated in 
previous studies that TNF-α (Murphy et al., 2002; Ruddle et al., 1990) alpha and IL-6 
(Samoilova et al., 1998) plays an important role in worsening of EAE.  The increase in 
the level of TNF-α and IL-6 was also observed in the study of Herman et al. 
Research evidences over a period of time also suggested that infectious agents 
may play a protective role in autoimmune diseases like MS. The inhibitory effect of 
bacterial infection in EAE and MS has also been observed (Ben-Nun et al., 1995; Ben-
Nun and Yossefi, 1992). Ben-Nun and collogues has shown that the SJL/J mice pre-
exposed to Mycobacterium tuberculosis (Mt) and some other bacterium, developed 
long-lasting resistance to EAE and also identified a 12-kDa protein fraction, belongs to 
heat shock protein family, to be responsible for this protective effect. They also 
speculated that the protection in these mice from EAE arises due to the result of similar 
T-cell epitopes between mycobacterial heat shock protein and different myelin proteins. 
Moreover, some role of parasitic infection also has proven protective in EAE, which 
generally shift the immunological balance towards Th2
To induce a mild infection and to increase the survival of animals after infection, 
they are generally treated with antibiotics. Antibiotic treatment seems to affect the EAE 
in both ways, some antibiotics seems to be protective in EAE while some are not (Wang 
et al., 2009). The precise mechanism of how antibiotic treatment influences EAE is not 
clear so far. Through a short term treatment in any case seems to have no direct 
neuroprotective effect in the EAE (Herrmann et al., 2006). However, antibiotic treatment 
like ceftriaxone may cause rapid degradation of bacterial components which may 
probably do not reflect the normal infectious condition. Therefore the impact of infection 
in animal models should be evaluated without intervention of any antibiotic treatment. 
Hence for that reasons, chronic infection model without any antibiotic treatment would 
be more appropriate to evaluated impact of infection in EAE. 
-cell type. From the above 
research evidences it could be speculated that infections increases the natural 
propensity of these animal models, hence they developed resistant towards an 
autoimmune disease. 
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1.6.2:  Chronic infection model 
Infections in prostheses lead to serious complications. This is due to the formation of a 
bacterial biofilm, antibiotic tolerance and an altered activity of phagocytic cells 
associated with the foreign body. The main causative agent for this is S. aureus. 
Therefore, by taking advantage of this microorganism Werner Zimmerl and co-workers 
in 1982 established an experimental model chronic foreign body infection in guinea pig 
to study pathogenesis of foreign body Infection (Zimmerli et al., 1982). Later on Lucet et 
al established this model in Wistar rat. A chronic infection is achieved by implantation of 
a foreign body, in which the bacteria can adhere (Lucet et al., 1990; Murillo et al., 2006). 
In the study of Lucet et al tissue cages were implanted under the skin and infected with 
S. aureus to test the effect of different antibiotics. The inoculum dosage of 105-106
Shapira and colleagues (2002) implanted tissue cages made of titanium wire in 
mice and immunized them 2 weeks later with mouse spinal cord homogenate (MSCH). 
Five days after immunization, animals were infected with heat killed Porphyromonas 
gingivalis, which resulted in a more severe EAE (Shapira et al., 2002). They concluded 
that this effect is due to more peripheral inflammation. However, infection with heat 
killed bacterium does not represent the true infectious condition and does this infection 
leads to the chronic systemic inflammation was also not clear. Hence in best of my 
knowledge, there is no such study with the true chronic bacterial infection on an animal 
model of MS has been performed until now. 
 
colony forming unit (CFU) was used to establish this infection model. However, this 
inoculums dosage may vary with the depending on the strain of the rat. 
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2. AIM OF THIS WORK 
The course of Multiple Sclerosis, a chronic autoimmune disease, can be influenced by 
systemic infections. The common notion is that, bacterial infections worsen disease 
symptoms and to lead to enhanced neurodegeneration. However, the underlying 
biological mechanisms by which bacterial infections influence the disease course and 
neurodegeneration in MS are complex and poorly understood. Most of the previous 
experimental studies on animal model used the bacterial component to induce the 
systemic inflammation to mimic the situation of viable bacterial infection. Further, the 
Inflammation induced by the bacterial components or by a bacterial infection induces 
similar effects on the course of the disease has not yet proven. Furthermore, the kind of 
infection (acute and chronic) even more the type of bacteria used may also a have 
varying impact on the course of disease and neurodegeneration. 
So our objective in this study was 
1. To investigate the influence of acute Escherichia coli (E. coli) infection on the 
clinical course and the extent of neurodegeneration in experimental autoimmune 
encephalomyelitis, when infection was induced during preclinical and clinical 
phase of disease 
2. Establish a chronic infection model in female BN rats  
3. To investigate the influence of chronic Staphylococcus aureus (S. aureus) on 
the clinical course and the extent of neurodegeneration in experimental 
autoimmune encephalomyelitis, when infection was induced in the preclinical 
phase of disease 
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3. MATERIALS AND METHODS 
3.1: Materials: - Materials used in this thesis are listed in the following tables. Unless 
otherwise stated, materials were purchased from companies located in Germany. 
3.1.1: Instruments 
Cell counting chamber 
Neubauer cell chamber      Superior-Marienfeld 
Centrifuges 
Allegra X 22R     Allegra 
5415C     Eppendorf 
5425 R     Eppendorf   
Cryotome 
CM 30505     Leica  
Luminex 
Bio-Plex 200     Bio-Rad 
Fridge and freezers 
GNP 3656 (4°C)      Liebherr 
KDR40420GB/01 (4°C)      Bosch 
GSS 3626 (-20°C)      Liebherr  
KSD 3142 Premium (-20°C)      Liebherr 
GNP 3056 (-80°C)      Liebherr  
Flat cooler 
TUC2     Pathhisto 
Flow cytometer 
BD FACSCalibur     BD Biosciences 
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High thermal flattening table 
 HI 1220     Leica 
Hood 
Laminar air hood                  Thermo Scientific 
Magnetic stirrer 
RH basic     IKA 
IKAmag reo     IKA 
Microscope 
Axiopaln 2     Carl Zeiss 
axiovert 200      Carl Zeiss 
Axiostar plus     Carl Zeiss 
Stemi 2000-C     
Examiner Z1     
Carl Zeiss 
SM2000R     Leica 
Pipette 
2.5 µl, 10 µl, 100 µl, 200 µl, 1 ml, 5 ml     Eppendorf 
2.5 µl, 10 µl, 100 µl, 200 µl, 1ml     Gilson 
Carl Zeiss 
Microtome 
50 µl, 200 µl (Multichannel)      Eppendorf 
pH Meter  
PB-20     Sartorius 
Vortex 
MS 3 basic     IKA 
Vortex-Genie 2     IKA  
Weighing balance 
BL2105     Sartorius 
BL 3100     Sartorius 
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3.1.2: Consumables  
Name Company 
Aluminium foil Carl Roth 
Blood agar plates Department of Microbiology Göttingen 
Centrifuge tubes (0.5-, 1.5-, 2-ml)  Eppendorf 
Centrifuge tubes (15-50 ml)  BD Falcon 
Cover slip (24*48, 24*60)  Menzel-glaser 
Cuvette Carl Roth 
Filter tip (10-, 200-, 1000-,1250-µl)  Greiner Bio One, Sarstedt 
Gloves Meditrade 
Microscope slides (Superfrost plus)  Thermo Scientific 
Microtome blade Feather 
Needles (28G, 23G, 27G)  BD Eclipse 
Nitrile gloves Meditrade 
Nunc 96 well plates Apogent 
Para film Pechiney Plastic Packaging 
Pasture pipette bulb Carl Roth 
Petri dish 15 mm BD Biosciences 
Pipette tips (10-, 100-, 200-, 1000-µl)  Sarstedt 
Plastic wares Vitlab 
PMMA cover slip  for implant (Self made)  Carl Roth 
Safety needle (26G)  Sarstedt 
Syringes (2 ml, 5 ml,10 ml)  BD Biosciences 
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3.1.3: Chemicals, miscellaneous reagents and commercial kits. 
Name Molecular formula 
/ Abbreviations 
Company 
ABC-peroxidase solution  Vector Labs 
Agar  MERCK 
Albumin bovine serum  Sigma-Aldrich 
Ammonium chloride NH4 Sigma-Aldrich Cl 
Ammonia  Merck  
Bio-Plex Pro ™ Rat Cytokine 
Th1/Th2 Assay #171-K1002M 
 Bio-Rad 
Brain-heart infusion medium  Department of Microbiology 
Goettingen 
Bromphenol blue C19H9Br4NaO5 Fluka S 
Chloral hydrate C2H3Cl3O Fluka 2 
Citric acid  Merk 
DAB substrate Kit  Vector Labs 
Disodium hydrogen phosphate Na2HPO4*2H2 MERCK O 
Ethyl alcohol 99% pure C2H5 Chemie-Vertrieb GmbH OH 
Ethyl alcohol ultra pure C2H5 Merk OH 
Ethylenediaminetetraacetic acid EDTA Carl Roth 
Formalin  Merck 
Fluorogold  Fluorochrome 
Glacial acetic acid  C2H4O Merk 2 
Glucose 5%  B. Braun 
Glycerin C3H8O MERCK 3 
HCl-ethanol  Merk 
Mycobacterium tuberculosis 
(Heat inactivated) (strain H 37 
RA)  
 Difco Laboratories 
Hydrochloric acid (32%)  HCl Carl Roth 
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Hydrogen peroxide 30% H2O MERCK 2 
Immersion oil for microscopy  Zeiss 
Isopropanol C3H8 Carl Roth O 
Luria Broth  Fluka 
Lithium carbonate  Li2CO Fluka 3 
Myelin oligodendrocyte 
glycoprotein 
MOG Institute of Neuropathology, 
Göttingen 
Igd 
Mount medium (IF)   Thermo Scientific 
Mount medium (IHC)   Carl Roth 
Nitric acid HNO J.T.Baker 3 
Paraformaldehyde PFA Carl Roth 
Periodic acid  Sigma-Aldrich 
Potassium phosphate K2HPO Sigma-Aldrich 4 
Potassium chloride KCl MERCK 
Potassium phosphate KH2PO Sigma-Aldrich 4 
Schiff's reagent  Sigma-Aldrich 
Silver nitrate AgNO Carl Roth 3 
Sodium azide N3 Sigma-Aldrich Na 
Sodium chloride (0.9%)  B. Braun 
Sodium citrate Na3C6H507*H2 MERCK 0 
Sodium thiosulfate Na2O3S Fluka 2 
Sodium chloride NaCl MERCK 
Sodium phosphate dibasic Na2HPO Sigma-Aldrich 4 
Solvent blue 38  Sigma-Aldrich 
Sucrose C12H22O Fluka 11 
Triton X-100  Sigma-Aldrich 
Vaseline  Lever Faberge 
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3.1.4: Surgical instruments 
Instruments Company 
Cauterizer Fine Science Tools 
Forceps Fine Science Tools 
Hamilton syringe Hamilton Messtechnik GmbH 
Hemostatic clamp Fine Science Tools 
Infuse/withdraw syringe pump (KDS 310) KD Scientific 
Light source micrcoscope KL 1500 LCD Schott 
Micro motor (FM3545) Foredom 
Rongeurs Fine Science Tools 
Scalpel Fine Science Tools 
Scissors Fine Science Tools 
Steriotactic frame (Model 963, Ultra Precise ) Kopf 
Suture Ethicon 
Teflon tube Carl Roth 
3.1.5: Pharmacological products 
Product Company Application 
Ceftriaxone Hikmapharma Antibiotic 
Desitin DesitinArzneimittel GmbH Wound cream 
Glucose 5% B. Braun Melsungen Infusion (Energy) 
Isoflurane Abbott Inhalation Anesthesia 
Ketamine Atarost Anesthesia 
Metapyrin Serum-Werk Pain killer 
Rimadyl Pfizer Painkiller 
Xylazine (2%) Albrecht Anesthesia 
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3.1.6: List of primary antibodies 
Antibody Conjugate Company Application 
CD134 (OX-40)  FITC Biolegend Flow-cytometry 
CD3 Alexa fluor 647 Biolegend Flow-cytometry 
CD3 Biotin Biozol IHC 
CD4 PE-Cy5 Biolegend Flow-cytometry 
CD45-RA PE Biolegend Flow-cytometry 
CD8 PE Biolegend Flow-cytometry 
CD 68 (ED1)  Biotin AbDserotec IHC 
3.1.6: List of secondary antibodies and purified protein  
Antibody (species) Company Conjugate Application 
Goat anit-mouse IgG Vector Lab HRP IHC 
Goat anit-rabbit IgG Vector Lab HRP IHC 
Goat anit-mouse IgM Vector Lab HRP IHC 
Streptavidin (for 
biotinylated primary Ab 
Biolegend PE-Cy5 Flow-cytometry 
3.1.7: List of computer softwares 
Program Company Application 
Adobe Illustrator CS2 Adobe Systems Image processing 
Adobe Photoshop 4.0 Adobe Systems Image processing 
AxioVision Carl Zeiss Image processing 
Definiens Developer XD software Definiens Image processing 
FACSCalibur BD bioscience Flowcytometric analysis 
Bio-Plex Manager 6.0 Biorad Cytokine analysis 
Office Excel  Microsoft office 2007 Data analysis 
Prism  GraphPad Data analysis 
SPSS IBM Data analysis 
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3.1.8: Buffers and other stock solutions 
3.1.8. A: Phosphate buffer 10x for 1liter 
 Chemicals Weight 
1 Sodium chloride 80 g 
2 Potassium chloride 2 g 
3 Disodium hydrogen phosphate 21.6 g 
4 Potassium phosphate 2 g 
All the components were mixed in one liter of distilled water and pH (7.4) was adjusted 
by using 1 molar NaOH and HCl. 
3.1.8. B: Citrate buffer 
6 g Sodium citrate was added in three liter of water and pH was adjusted to 6.0. 
3.1.8. C: Developer stock solution for Bielschowsky silver staining 
 Chemicals Weight / Volume 
1 Formalin 10 ml 
2 Citric acid 0.25 g 
3 6% nitric acid 2 drops 
4 Distilled water 50 ml 
3.1.8. D: RBC lysis buffer 
5.349 grams of ammonium chloride mixed in 1 liter of PBS, pH was adjusted to 7.4.  
3.1.8. E: FACS buffer 
 Chemicals Weight / Volume 
1 Bovine serum albumin 10 g 
2 Sodium azide 1 g 
3 PBS  1 liter 





Female brown Norway rats, 8 to10 weeks of age, weighing between 150-175 grams 
were used in all experiments. They were obtained from Charles River (Sulzfeld; 
Germany) and kept under environmentally controlled and pathogen-free conditions. 
They were given water and standard rodent chow ad Iibitum. In case animals had 
severe EAE they were given 5 ml of glucose and sterofudin (1:1) and softened food 
inside side the cage during the experiment. All experiments involving animal use were 
performed in accordance with the relevant laws and institutional guidelines of University 
Medicine Göttingen. These experiments have been approved by the local authorities of 
Braunschweig, Germany.  
3.2.2: Immunogen 
Recombinant rat MOG Igd
3.2.3: Bacterial inoculum preparation 
, corresponding to the N-terminal sequence of rat MOG (aa 1-
125), was expressed in E. coli and purified to homogeneity by chelate chromatography 
(Weissert et al., 1998). The purified protein was then dialyzed against 0.01 M sodium 
acetate (pH 3) to obtain a preparation that was stored at -80°C for further use.  
3.2.3.1: Escherichia coli 
The E. coIi (Strain k1, originally isolated from the CSF of a child with meningitis) 
inoculum was provided by Dr. Roland Nau, Institute of Neuropathology, University 
Medicine Göttingen. A single colony of E. coli was inoculated into Luria Broth medium. 
Bacteria were harvested after 4 hours of incubation at 37°C. To determine the exact 
concentration of bacteria, the inoculum was serially diluted in 0.9% NaCl and plated on 
blood agar plate (Provided by Medical Microbiology, University Medical Center 
Göttingen) and incubated for 24 h at 37°C. Bacterial concentrations were determined by 
quantitative plating on blood agar plates and aliquots were kept at -80°C until further 
use. 
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3.2.3.2: Staphylococcus aureus  
The S. aureus strains ATCC 29213 (kindly provided by Raimund Lugert from the 
University Medicine Göttingen), Newman ATCC 25904  and the extracellular adherence 
protein (Eap) deficient strain of ATCC 25904, AH12 (kindly provided by Markus Bischoff 
from the Institute for Medical Microbiology and Hygiene, University of Saarland; 
Germany)  were used in these experiments. A single colony of the respective S. aureus 
strain was inoculated into brain heart infusion medium and incubated for 20 hours at 
37°C in a shaking incubator. Afterwards, 50 µl of the bacterial culture grown for 20 
hours were inoculated into 10 ml of fresh brain heart infusion medium and again 
incubated at 37°C in a shaking incubator. Bacteria were harvested after 6 hours of 
incubation at the time when the bacterial culture reached the log phase of growth. 
Bacterial concentrations were determined by quantitative plating on blood agar plates, 
and aliquots were kept at -80°C until further use. 
3.2.4: Retrograde labelling of RGCs 
By retrograde axonal transport, the RGCs were selectively labeled and visualized for 
fluorescence microscopy. Retrograde labelling of retinal ganglion cells (RGCs) and 
tissue cage implantations were done during a single anaesthesia 2 to 3 weeks before 
the MOG-immunization. Rats were anesthetized by intraperitoneal injection of ketamine 
(0.95 ml/kg) and xylazine 2% (0.25 ml/kg) and positioned in a stereotaxic frame. The 
skin was incised mediosagittally, and holes were drilled into the skull above each 
superior colliculus (6.8 mm dorsal and 2 mm lateral from bregma). 2 µl of fluorescent 
dye fluorogold (5% in distilled water) were injected into both superior colliculi at a rate of 
0.50 µl per min. For pain relief, animals received metapyrin in drinking water (3ml/L) 2 
days before the start of surgical procedure, which were continued until day 8 of post 
surgical procedure. 
3.2.5: Tissue cage preparation and implantation 
Rigid polytetrafluoroethylene (Teflon) tissue cages  (internal and external diameter of 8 
and 10 mm respectively, length 25 mm) perforated by around 100 regularly spaced 
holes (diameter 1 mm) containing two polymethylmethacrylate (PMMA) cover slips per 
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tissue cage sealed at both ends with a suture, were used as a foreign body implant. A 
cutaneous incision in the left flank was made under anaesthesia, and one autoclaved 
tissue cage was subcutaneously implanted under sterile conditions into each animal. 
After fluorogold (FG) injection and tissue cage implantation, the wounds were sutured at 
place of implantation and given 6ml of a glucose 5% / Sterofundin solution (1:1) (1/3 
intraperitoneally and 2/3 subcutaneously). After tissue cage implantation and  colliculus 
injection animals were treated with Rimadyl 10µl / 100g / animals (analgesia) followed 
by metapyrin (3ml/L) in drinking water until 8 days post surgical procedure. 
3.2.6: Induction of acute and chronic infection 
To study the effect of acute infection in EAE animals were infected intraperitoneally with 
106 CFU of E. coli in 200 µl of 0.9% saline. Control rats received an equal volume of 
saline. The chronic infection with S. aureus was induced by injection of 200 µl of 
bacterial culture diluted in 0.9% saline containing 2x107
3.2.7: Experimental setup and timeline  
 colony forming units (CFU) into 
the agar of the tissue cage. Control animals received 200 µl saline into the tissue cage. 
3.2.7.1: Experimental design for acute infection model  
Number of animals were used in these experiments was 57. Immunized animals were 
randomly assigned to four different groups. Animals were infected intraperitoneally with 
E. coli either on day 7 post immunization (early group; Fig 3.2.1.A) or on day 1 of clinical 
manifestation of EAE (late group; Fig 3.2.1. B). Control rats received an equal volume of 
saline. To elucidate whether infection could shift the time point of disease onset in 
MOG-EAE infection was performed during asymptomatic phase of the disease (day 7 
post immunization). Number of animals used was 28 (n=15, early infection; n=13, 
control) excluding the animals which died after E. coli infection or were sacrificed for 
ethical reasons.  
To reflect the clinical situation in MS patients, animals were infected on day 1 of 
EAE (late group). Here we addressed the question whether the infection could 
aggravate the clinical symptoms of EAE. Number of animals used for this experiment 
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was 29 (n=15, late infection; n=14, control). Animals which either did not show clinical 
signs of EAE or died after E. coli infection were not included in the analysis of late 
infection group. 
 
Fig 3.2.1: Experimental design. Fluorogold (FG) injection was performed 2 weeks prior to 
MOG immunization. A; In early infection group, intraperitoneal injection of E. coli or saline was 
performed on day seven post immunization followed by antibiotic treatment for three 
consecutive days. Day12 - day17 was the usual time point of clinical onset of disease. Animals 
were followed until day 8 of EAE or day 21 post immunization in case of clinically healthy 
animals. B;  In late infection group intraperitoneal injection of E. coli or saline was performed on 
the day of clinical manifestation of the disease. Animals were followed until day 8 of EAE. At the 
end of experiment optic nerve was taken out for histopathological analysis, the retina was flat-
mounted for quantification of retinal ganglion cells.  
To confirm the systemic infection, blood samples were collected from the tail vein under 
inhalation anaesthesia with isoflurane (n=8 for each group) 24 hours after the infection 
in the late infection group. Plating of blood samples was performed on blood agar plates 
under sterile conditions. Animals were followed until day 8 after the clinical 
manifestation of the disease (EAE d8), or day 21 post immunization in case of absence 
of EAE symptoms. To ensure the survival of E. coli infected animals, antibiotic treatment 
was started 36 hours after the infection and was followed for three consecutive days at 
a difference of 12 hours in both the groups. 
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3.2.7.2: Experimental design for chronic infection model and timeline 
Previously Lucet and co-workers established an experimental model for chronic foreign 
body infection by inoculation of 105-106 CFU of S. aureus into the implanted tissue 
cages of male Wistar rats (Lucet et al., 1990). However, due to variation in the strain of 
the rat (female BN rat), with the similar setup, 109
 
Fig 3.2.2: Experimental setup. Tissue cages were made by using a piece of Teflon plastic (1). 
Around hundreds of drills were made (2) and 2 PMMA cover slip was placed inside the tissue 
cage (3) stitched at both ends (4). Animals were anesthetised and fluorogold was injected 
stereotactically into the superior colliculus (A). Hair was removed (B) and an incision was made 
in the flank of the animals (C). One tissue cage per animal was placed in the incised region (D). 
Stitching was done (F) and animals were left 3 weeks for complete recovery. 
 CFU of S. aureus was insufficient to 
induce a chronic infection. 
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Agar is an excellent substrate for the growth of the microorganism and indigestible for 
many micro-organisms and for animals. Thus to provide more surface area for the 
attachment of bacteria we injected 400 µl of 2.3% semi-solid agar into the implanted 
tissue cage using a 27G needle 6 days prior to the infection (corresponding to 2 days 
prior to immunization). In such optimized condition animals showed a chronic infection 
even 3 weeks after inoculation of bacteria in the tissue cages of all the animals. 
Inoculum dosage was also optimized between inoculum concentrations of 105 to 109 
CFU to establish the chronic infection in this animal model. However, in the absence of 
agar injection in to the tissue cage, 109
 
Fig 3.2.3: Experimental timeline. Tissue cage (TC) implantation and fluorogold (FG) injection 
was done 2 to 3 weeks prior to myelin oligodendrocyte glycoprotein (MOG) immunization. Agar 
was injected into the TC 2 days before immunization. Injection of Staphylococcus aureus (S. 
aureus) or saline was performed on day 4 post immunization (pi). Animals were followed until 
day 8 of experimental autoimmune encephalomyelitis (EAE) or day 21 pi in case of clinically 
healthy animals. To monitor the infection, blood samples were taken throughout the whole 
experiment. Tissue was harvested from the optic nerve for histopathological analysis; retina was 
flat-mounted for quantification of retinal ganglion cells. Tissue cage fluid (TCF) was checked for 
the presence of bacteria. 
 CFU were non-infective. Before the agar 
injection, tissue cage fluid (TCF) was obtained percutaneously from all animals and 
checked for the sterility by plating on blood agar plates. Animals were excluded from the 
experiment if they had contaminated TCF.  
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Two days after the agar injection in tissue cage, immunization was done and 
considered day zero of immunization. Infection was performed on day 4 post 
immunization (pi). This infection time point was chosen to elucidate whether infection 
modulates the course of EAE. In the first set of experiment (n=30), one animal group 
was infected with a wild-type strain of S. aureus (ATCC 29213). The corresponding 
control group received saline. To prove our hypothesis of anti-inflammatory effect of 
extracellular adherence protein (Eap), animals (n=26) were again randomized into the 
three different groups. One group was infected with the wild-type S. aureus strain 
(ATCC 25904). A second group was infected with S. aureus strain deficient for Eap 
(AH12), which is an isogenic mutant of the wild-type Newmen strain of S.aureus (ATCC 
25904). The corresponding control group received saline. Animals were followed until 
day 8 after the clinical manifestation of the disease (EAEd8) or day 21 post 
immunization (pi) in case of clinically healthy animals. At the end of the experiment, 
TCF was obtained percutaneously from all (infected and noninfected) animals. TCF was 
checked for the presence of bacterial colonies by plating on blood agar plates. 
3.2.8: Induction and evaluation of EAE  
Rats were anesthetized by inhalation anaesthesia with isoflurane and injected intra-
dermally at the base of the tail with a total volume of 200 µl inoculum, containing 50 µg 
recombinant rat MOGIgD (kindly provided by C. Stadelmann, Institute of Neuropathology, 
University Medicine Göttingen) in saline emulsified (1:1) with complete Freund’s 
adjuvant  containing 200 µg heat-inactivated Mycobacterium tuberculosis. Rats were 
scored for clinical signs of EAE and were weighed daily. The signs were scored as 
follows: grade 0, no symptoms; grade 0.5, distal paresis of the tail; grade 1, complete 
tail paralysis; grade 1.5, paresis of the tail and mild hind limb paresis; grade 2.0, 
unilateral severe hind limb paresis; grade 2.5, bilateral severe hind limb paresis; grade 
3.0, complete bilateral hind limb paralysis; grade 3.5, complete bilateral hind limb 
paralysis and paresis of one front limb; grade 4, complete paralysis (tetraplegia), 
moribund state, or death.  
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3.2.9: Blood leukocyte counts  
To monitor the local application of S. aureus in the tissue cage induces the systemic 
inflammation, leukocyte counts were performed in peripheral blood every second day 
until day 8 after MOG immunization and then at an interval of 3 days until day 20 pi. 
Blood samples were taken sublingually after inhalation anaesthesia with isoflurane. A 
total of 10 µl of blood sample was diluted in 190 µl of 4% glacial acetic acid, and 
leukocyte counting was performed in a Neubauer haemocytometer. 
3.2.10: Lymphocytes count after S. aureus infection  
Flow cytometry for lymphocyte counting was performed in blood on day 4 post 
immunization (pi) prior to infection and 2 days after infection at the time when the 
leukocyte counts reached their peak. In brief, 100 µl blood taken sublingually was 
collected in 250 µl of 5 mM EDTA prepared in isotonic PBS. Samples were washed 
once with PBS, and RBC lysis buffer (0.1 M ammonium chloride in PBS) was added in 
each sample. Samples were left at 4°C for 10 minutes and washed once with PBS. 
Samples were divided in two equal parts. In first set of staining a total of 100 µl of FACS 
buffer (PBS + 1% BSA + 0.1% NaN3
3.2.11: Cytokine multiplex assay  
) containing florescent tagged anti rat-CD45RA 
(BioLegend Cat# 202307) and anti rat-CD3 (BioLegend Cat# 201408) antibodies along 
with the beads were added in each samples at a dilution of 1:200. Similarly in the 
second set of staining a total of 100 µl of FACS buffer containing florescent tagged anti 
rat-CD3 (BioLegend Cat# 201408), anti rat-CD8a-PE (BioLegend Cat# 201705), anti 
rat-CD134 (OX-40) (BioLegend Cat# 204503) and anti rat-CD4-AF647 (BioLegend Cat# 
201513) antibodies were added in each samples at the similar dilution of 1:200. 
Incubation was done for 45 minutes at 4°C in the dark. The cells were washed once 
with PBS and re-suspended in 200 µl of FACS buffer prior to flow cytometric analysis. 
Analysis was performed by four-color flow cytometry using a FACSCalibur and FacScan 
software (BD; Goettingen; Germany). 
Blood samples were collected at the end of the experiment by puncturing the heart with 
an 18G syringe before the perfusion of animals and kept on ice for 30 minutes. Serum 
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was collected by centrifuging all the samples at 3000 RPM for 5 minutes at 4°C. 
Aliquots were kept at -80°C until further use. A Luminex assay kit (Bio-Plex Pro™ Rat 
Cytokine Th1/Th2 Assay #171-K1002M), containing premixed coupled magnetic beads 
and detection antibodies for detecting 12 rat cytokines (IL-1 alpha, IL-1 beta, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-12, IL-13, TNF-alpha, INF-gamma, GM-CSF) was used for 
measurement of cytokine concentrations in serum samples collected at the end of the 
experiment. The total number of animals used in this cytokine assay was 25 (n = 11 
infected with wild-type strain of S.aureus (ATCC 25904); n = 9 infected with Eap-
deficient of S.aureus (AH12); n = 5 noninfected control). Quantification of cytokines was 
performed according to the manufacturer's instructions. Measurement was performed 
by using a Bioplex 200-system based on the Luminex xMAP-technology (Bio-Rad, 
Hercules, CA, USA). The signal detection occurred using the Bioplex 200-system and 
the Bioplex Manager Software version 6.0. 
3.2.12: Histopathology and immunohistochemistry 
Retinas were removed for counting of RGCs; paraformaldehyde (PFA)-fixed paraffin-
embedded optic nerves (ONs) were taken for histopathological evaluation. After 
perfusion of rats with 4% PFA, ONs were post-fixed in 4% PFA for 24 h and embedded 
in paraffin. All histopathological analysis was performed on paraffin embedded ON 
cross sections representing three different levels of an ON.  
3.2.12.1: Staining and quantification of demyelination 
Luxol Fast Blue staining was used to evaluate demyelination on 2 µm thick optic nerve s 
following standard protocol was used for staining 
 Sections were deparaffinzed in xylene (2 times for10 minutes), followed by 
rehydration in descending alcohol series (100%-, 2 times for 3 minutes; 96%-, 
alcohol) for 3 minute each.  
 Thereafter, the sections were incubated in LFB solution overnight at 60°C 
 Sections were serially dipped in 90% alcohol, 0.05% lithium carbonate 
solutions, and in 70% ethanol for 1 minute each. 
                                                                                                                          MATERIALS AND METHODS 
35 
 
 Sections were incubated in 1% periodic solutions for 5 minutes and followed 
by a wash in running tap water for 5 minutes and further dipped in distilled 
water. 
 Then sections were incubated in Schiff's reagent for 30 minutes at 4°C 
followed by a washing in running tap water for 5 minutes. 
 Sections were counter stained with hematoxylin solution for 7 minutes and 
dipped in distilled water and HCl-ethanol for few seconds. 
 Sections were washed in running tap water for 10 minutes and dipped in 
distilled water followed by dehydration in ascending ethanol series (50%-, 
70%-, 90%-, 96%- ethanol briefly, 100%- 2 times for 1 minute, xylene 2 times 
for 3 minutes).  
 Slides were mounted and cover slipped and used for quantification.  
3.2.12.1.1: Quantification of demyelination 
Photos of vertical sections were taken using an AxioCam MR Microscopy camera 
(Zeiss, Göttingen; Germany). The images were processed using Zeiss AxioVision 4.2 
software to evaluate the demyelinated area as a percentage of the whole ON cross 
sections.  
3.2.12.2: Axonal count and data evaluation 
To illustrate the axonal counts in the optic nerve, the paraffin sections were stained by 
the Bielschowsky silver staining. An evaluation was performed on paraffin embedded 
0.5 µm thick sections of the optic nerve.  
Following protocol was used for the staining and data evaluation: 
 Sections were deparaffinized in xylene (2 times,10 minutes each), followed by 
rehydration in descending alcohol series (100%, 2 times, 3 minutes; 96%-, 
90%-, 70%-, 50%- alcohol) for 3 minute each.  
 Thereafter, the sections were incubated for 20 minutes in 20% silver nitrate 
solution.  
 Dipped in water for a short time.  
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 Ammonia was added in 20% silver nitrate solution drop wise until solution 
turns from bright to dark and turned bright again. 
 The optic nerve sections were then transferred back into the silver nitrate -
ammonium solution and incubated for 15 minutes in the dark.  
 6 - 8 drops of a developer solution were added.   
 Few slides were incubated in silver ammonia solution and looked for dark 
brown coloration of optic nerve microscopically.  
 Slides were washed in distilled water and incubated in 2% sodium 
thiosulphate for 2 minutes. 
 Slides were washed in running tap water and dehydrated in ascending 
ethanol series (50%-, 70%-, 90%-, 96%- ethanol briefly, 100%- 2 times for 1 
minute, xyline 2 times for  3 minute each), mounted and cover slipped. 
3.2.12.2.1: Quantification of axonal densities in optic nerve 
To quantify the axonal density, 0.5 µm thick slices of ONs were stained by Bielschowsky 
silver impregnation staining to visualize axonal structures. Automated quantification of 
axonal densities was performed on high magnification pictures (1000x) applying a 
custom-programmed script in Cognition Network Language based on the Definiens 
Cognition Network Technology® platform. Briefly, the programmed script first 
discriminates between tissue and background (no tissue) by spectral difference 
detection. Subsequently, the area of detected tissue (region of interest, ROI) is 
calculated and “axonal structures” within this ROI are detected based on their dark 
black color. To discriminate between nucleoli of inflammatory cells and axons (which 
both structures are stained black in Bielschowsky silver impregnation) only black 
structures without a faint brown-stained circumference (nucleus) were further classified 
as axonal structures. In a next step, multiple axons in direct contact with each other 
were further split into the corresponding individual axons if the splitting improved the 
elliptic shape of an axon. Within each area ROI, the total number of axons was 
calculated. The density of axons in each ON measured in at least nine standardized 
microscopic fields of each ON. The mean axon density was calculated for each ON and 
expressed as axons/mm2. However, in the experiment with acute infection model 
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infected with E. coli group and respective control group, axonal density was measured 
semi-quantitatively by Bielschowsky silver impregnation staining on 2 µm thick vertical 
section of ONs in three standardized microscopic field per . In brief axonal density was 
determined in vertical sections of the ON by point sampling using a 25-point Zeiss eye - 
piece. The number of points crossing axons was measured as a fraction of the total 
number of points of the stereological grid.  
3.2.12.3:  Immunohistochemistry 
Immunohistochemistry was performed in serial sections of paraffin-embedded ONs. 
ED1 macrophages/ activated microglia and CD3-positive 
 The paraffin embedded slides were deparaffinised by placing twice in xylol for 10 
minute each. 
cells were detected in cross 
sections using biotin-avidin detection. Spleen sections served as positive control for 
ED1 staining. The following standard protocol was followed for immunohistochemical 
analysis; 
 Sections were rehydrated in descending ethanol concentration for 3 minute each 
(100% 2 times, 96%-, 90%-, 70%-, 50%- ethanol) followed by placing them in 
water. 
 Antigen retrieval was performed by heating the slides into microwave in citrate 
buffer for 10 minutes at 800 watt and 5 minutes for 560 watt. 
 Slides were allowed to cool down for 20 minutes at room temperature. 
 Quenching of endogenous peroxidise was done by dipping the slides into 3% 
H2O2
 Slides were washed with PBS (3 times for 5 minutes).  
 for 10 minutes at room temperature. 
 Blocking was done for 1h at room temperature with 10% serum (ED1) or in 10% 
serum+ 2% BSA (CD3).  
 Primary antibodies were applied in appropriate dilutions (1/500 for ED1 and 
1/200 for CD3).  
 Slides were incubated at 40C (For ED1, 12-16 h; for CD3, 20-24 h).  
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 Washing was done with PBS (3 times for 5 minutes) followed by incubation with 
secondary antibody 1 h at room temperature. 
 Washing with PBS (3 times for 5 minutes) was done. 
 Sections were incubated with VECTASTAIN® ABC Kit (Vector Burlingame; USA) 
for 1 h at RT followed by washing with PBS (3 times for 5 minutes).  
 Development was done by using DABI kit.  
3.2.12.3.1: Quantification of ED1 positive cells  
The evaluation of ED1 positive cells was performed using the following score: 0, no 
labelled cells; 1, a few ED1 positive cells (number countable) in at least one of the three 
cross sections of an ON; 2 infiltration of less than 10% of the ON  area with ED1 
positive cells (number not countable) in at least one of the three cross sections of an 
ON; 3, infiltration of 10-50% of the ON  area with labelled ED1 positive cells in at least 
one of the three cross sections of an ON; 4, infiltration of 80% of the ON  area; 5, 
infiltration of more than 80% of the ON  area in at least one of the three cross sections 
of an ON.  
3.2.12.3.2: Quantification of T-cell infiltrates in the optic nerve 
CD3 staining for assessment of infiltration of CD3 positive cells across the BBB was 
performed on 0.5 µm thick slices of paraffin-embedded ONs using anti-CD3 antibody. 
CD3 positive cells were detected by biotin-avidin detection. Spleen sections served as 
positive control for CD3 staining. To quantify T-cell infiltrates in the ON, we used tissue 
studio that is based on Cognition Network Language (Definiens Cognition Network 
Technology; Definiens Developer XD software, Munich; Germany) In brief, CD3 stained 
sections were scanned using the 3D Histech 250 Flash slide scanner at 200 fold 
magnification. The area of interest (optic nerve) was first detected from the background 
by the colour spectrum. After segmentation, nuclei and CD3-positive cytoplasm were 
discriminated. Within each area of interest, the total number of CD3-positive cells was 
calculated and expressed as cells/mm2. 
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3.2.13: Quantification of RGC density 
Eyes were enucleated from the rat before perfusion and kept in PFA for 2 minutes and 
transferred to PBS. An incision was made by using a 23G syringe on the junction of 
Sclera and the cornea. Frontal part was removed along with the lens. Then vitreous 
humour present on the retinal surface was taken out carefully. Retinae were dissected, 
flat-mounted on glass slides, and examined by fluorescence microscopy (Zeiss, 
Axioplan 2) using a DAPI filter (315/395 nm). Retinal ganglion cell densities were 
determined by counting labelled cells in three areas (62,500 µm2
3.2.14: Statistical analysis 
 each) per retinal 
quadrant at three different eccentricities of 1/6, 3/6, and 5/6 of the retinal radius. Cell 
counts were performed following a blinded protocol. 
Data are presented as means ± SEM. Student’s t-test was used to analyze differences 
between two animal groups. Multiple comparisons were statistically evaluated by one-
way ANOVA using Prism 5 (GraphPad software). Mann-Whitney U test was used for the 
analysis of the EAE score (SPSS, IBM). Data presented as means ± S.E.M. of the daily 
score. A p-value (P) of < 0.05 was considered to be statistically significant and indicated 
as follows *, P < 0.05; **, P < 0.01; ***, P < 0.001. “n” indicate the number of animals. 
However, for RGCs counting n indicate the number of eyes used for counting. 




4.1: Acute E. coli infection and EAE  
Evidences from experimental and clinical studies indicated that that the progression of 
multiple sclerosis (MS) is influenced by systemic infection caused by bacteria. In most 
of the previous experimental studies only bacterial components were used to mimic the 
situation of the bacterial infection that probably might not be the real clinical condition. 
Therefore to address the impact of a viable bacterial infection in MS, we infected an 
animal model of MS with E. coli, which causes the vast majority of urinary tract 
infections. Moreover, we infected the animals at two different time points to address the 
question that does the time course of infection have any impact on the onset of the 
clinical disease symptoms, when infection was performed in the preclinical phase of 
disease (day 7 post imunization) “early infection group” and on the severity and 
aggravation of clinical disease course, when the infection was performed on day 1 of 
clinical manifestation of the disease (day 1EAE) “late infection group”. 
4.1.1: Intraperitoneal infection with E. coli induces systemic inflammation  
The common notion is that a bacterial infection induces changes termed as a sickness 
behavior, which reflects in animals in form of weight loss, rise in body temperature, 
increase in heartbeat counts, sepsis and sometimes as the death of the animal. 
In the early infection group, the animals were infected with E. coli on day 7 after 
MOG-immunization, whereas late infection group reflects the condition when infection 
was induced on the day of clinical onset of disease (day 1EAE). In the early infection 
group (Fig; 4.1.1 A) the animals infected with E. coli (n=15) showed significant weight 
loss after the infection compared to the control group (n=13; P < 0.01). This loss in 
weight of animals indicated a general sign of sickness behavior. These animals 
recovered their weight loss after antibiotic treatment. In contrast, in the late infection 
group (infected on day 1 EAE; Fig 4.1.1 B) the animals infected with E. coli (n=15) did 
not show any significant difference in weight loss compared to the control group (n=14; 
B; P = 0.69). 




Fig 4.1.1: Weight loss: Animals infected with E. coli on day 7 post immunization (A) showed a 
significant weight loss compared to the control group. No significant weight loss was observed 
in late infection group (B) compared to control. 
The loss in the weight was probably due to the fact that during the clinical 
disease course of EAE both infected and control groups lost their weight rapidly. 
Therefore, to confirm the systemic infection in a late infection group of animals, 24 
hours after the infection, blood samples were collected from the tail vein of animals 
infected with E. coli and from the respective control group (n = 8 in each group) under 
sterile conditions. Plating of blood samples was performed on blood agar plates, which 
showed a mean bacterial count (Log10
4.1.2: The influence of E. coli infection on clinical course of MOG-EAE 
 3.64 ± 3.32; P = 0.04) only in the animals 
infected with E. coli. No bacterial counts were detected in saline treated control animals. 
The bacterial detection limit was 100 CFU/ml. We also observed a mortality rate around 
20% due to E. coli infection in both early and late infection group. However, the data 
from these animals were not included in the analysis of the results. 
The “early infection” group infected animals did not show any significant difference in 
the mean cumulative clinical score in comparison to the control animals (0.9 ± 0.35, n 
=15 vs. 1.038 ± 0.39, n =13; P = 0.8; Fig 4.1.2 A). Also the onset of disease was similar 
in both the groups (13 days post immunization in the infection and 12 days post 
immunization in the control group). 
 




Fig 4.1.2: Mean clinical score. Infection with E. coli on day 7 post immunization (early 
infection group; A) had no impact on the time of clinical onset or severity of the disease in 
MOG-EAE. Infection with E. coli on day 1 EAE (late infection group, B) did not show any 
significant impact on the severity of the disease compared to the control group. Data are shown 
as means ± S.E.M. of the daily score.  
In the second set of experiments, infection with E. coli was induced on the day when the 
animals showed first clinical symptoms (late infection group). E. coli infection did not 
substantially modulate the course of EAE. Here, the mean cumulative score was not 
significantly differed between the group infected with E. coli and the respective control 
group (2.47 ± 0.22 n =15 vs. 2.71 ± 0.19 n =14; P = 0.51; Fig 4.1.2 B) at the end of the 
experiment. 
4.1.3: Infection with E. coli and neuropathological damage of the optic nerve 
Animals were sacrificed on either day 8 of clinical manifestation of disease or at day 21 
after immunization in the absence of clinically manifest disease. Histopathological 
analysis was performed on paraffin embedded optic nerve s. We determined the extent 
of demyelination of the ONs by Luxol Fast Blue staining. In the early infection group we 
did not observe any significant difference in demyelination of E. coli infected animals 
(62.90 ± 9.43%; Fig 4.1.3 A, G; n=15) compared to control group (79.18 ± 8.06%; P = 
0.20; Fig 4.1.3 B, G; n=13). Analysis of inflammatory infiltrates by ED1 staining  
revealed no significant difference in the animals infected with E. coli on day 7 post 
immunization (2.84 ± 0.39; Fig 4.1.3 C, H; n=15) compared to the saline treated control 
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animals (3.45 ± 0.3; P = 0.50; Fig 4.1.3 D, H; n=13).  Bielschowsky silver impregnation 
was performed to access the axonal loss of the ON. At day 8 of MOG-EAE, we 
observed a loss of (66 ± 7.64%; Fig 4.1.3 E, I; n=15) in the animals infected with E. coli. 
In the control group, the axonal loss did not differ significantly (82.19 ± 5.69%; P = 0.1; 
Fig 4.1.3 F, I n=13).  
 
Fig 4.1.3: Optic nerve (ON) histopathology for early group: A and B: Representative Luxol 
Fast Blue-stained s of ONs of an animal infected with E. coli (A) and an animal from respective 
control group (B). Representative examples for number of infiltrating ED1 macrophages / 
activated microglia detected in the ON of an E. coli infected animal (C) and an animal from 
noninfected control group (D). E and F: Bielschowsky’s silver impregnation of an ON  revealed 
no differences in axonal densities of MOG immunized animal infected on day 7 post 
immunization (E) compared to noninfected control animal (F). G, H and I represent the 
quantitative data for demyelination, inflammatory infiltrates and for axonal counts in both E. coli 
infected and control group.   
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In the experiment performed with “late infection” a similar scenario was observed. Here 
the extent of demyelination (77.06 ± 5.77%; n=15; for infected group; 72.87 ± 6.46%; 
n=14; for the control group; P = 0.63; Fig 4.1.4, A) and number of inflammatory 
infiltrates (3.944 ± 0.24; n=15; for infected group; 3.827 ± 0.26; n=14; for the control 
group; P = 0.74; Fig 4.1.4, B) did not show any significant difference between the group 
infected with E. coli and the saline treated control group. Moreover, we did not find any 
effect of E. coli infection on axonal loss as quantified by Bielschowsky silver 
impregnation (71.84 ± 5.03%; n=15; for infected group and 70.07 ± 5.39%; n=14; for the 
control group; P = 0.81; Fig 4.1.4, C). 
 
Fig 4.1.4: Optic nerve (ON) histopathology for late infection group: No significant difference 
was observed in quantitative data analysis for demyelination (A), inflammatory infiltrates (B) and 
for axonal counts (C) between the groups infected with E. coli and the respective control.  
In summary these results from the histopathological analysis performed on optic nerve 
cross sections indicated that the E. coli infection did not have any influence on 
demyelination, infiltration of inflammatory cells or on axonal damage.  
4.1.4: Impact of E. coli infection on loss of RGCs 
It is presumed that bacterial infections lead to enhanced neurodegeneration. Therefore 
to evaluate the impact of infection on neuronal damage in MOG-EAE after E. coli 
infection, numbers of surviving RGCs were counted on fluorogold labeled retinal flat 
mount. In the early infection group (Fig 4.1.5 A; n=25 each) RGCs density did not reveal 
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any significant difference between E. coli infected group (1411 ± 87.57/mm²) compared 
to corresponding control group (1248 ± 68.99/mm²; P = 0.15). 
 
Fig 4.1.5: RGCs counting: No significant differences were observed in a number of surviving 
retinal ganglion cells (RGCs) of the animals infected with E. coli either in preclinical phase of 
disease (A) or in clinical phase of disease (B). 
Furthermore, to know the impact of infection during the clinical course of the disease the 
RGCs counting performed in the late infection group of animals which (Fig 4.1.5 B; n=16 
each group) did not reveal any significant difference between the group infected with E. 
coli (967 ± 33/mm²) compared to the corresponding control group (1116 ± 78/mm²). 
However, the group infected with E. coli on day of onset of the disease showed a 
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4.2: Chronic S. aureus infection and EAE 
Several acute infection models have been used to study the impact of infection on the 
course of EAE and mostly showed a deleterious effect on severity of disease. However, 
most of these studies also used an immediate antibiotic treatment to ensure the survival 
of animals after the infection. These situations mask the impact of the infection alone 
since the modulatory role of these antibiotics in the progression of EAE has been 
proven (Melzer et al., 2008; Mor and Cohen, 2013). Moreover, there is no direct 
evidence of S. aureus or any other chronic infection causes modulation of the EAE. In 
this study to ensure the chronic infection, to achieve this tissue cage was implanted 
under the skin and infected with S. aureus which leads to the chronic infectious 
condition in this animal model. No antibiotic treatment was performed during the course 
of the experiment. 
4.2.1: Local infection with S. aureus leads to persistent systemic inflammation 
The animals were infected with S. aureus on day 4 post immunization (pi) into the 
previously implanted tissue cage. After infection we did not observe any significant 
weight loss in the animal infected with S. aureus (Fig 4.2.1). However, animals from the 
control group lost their weight once they start showing clinical sign of EAE.  
 
Fig 4.2.1: Weight loss: After infection no significant weight loss was observed in animals 
infected with S. aureus. 
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Therefore to confirm the persistent local infection in the animals we collected 
TCF (tissue cage fluid) from all animals under sterile conditions at the end of the 
experiment and plated the TCF on the blood agar plates. TCF obtained from infected 
animals contained a high number of bacteria (S. aureus), whereas no bacterial growth 
was observed in TCF from noninfected control animals. Due to the semi-solid 
consistency of TCF, which is probably due to the presence of agar, dilutions for a more 
exact determination of bacterial numbers were not possible. In this animal model the 
inoculation with 107 
 
Fig 4.2.2: Blood leukocyte counts: Leukocyte counts were performed in peripheral blood 
of the animals infected with S. aureus wild type and noninfected myelin oligodendrocyte 
glycoprotein (MOG)-immunized control animals. The leukocyte counts were found to be 
significantly higher in the group infected with S. aureus.  
CFU was optimal to induce the chronic infection. 
During the course of the experiment we did not observe the presence of bacteria 
in the peripheral blood of animals. Therefore to monitor the local application of bacteria 
induced systemic inflammation, blood leukocyte counts were performed in peripheral 
blood samples until day 20 pi (corresponding to day 16 post infection). Here, we 
observed that the leukocyte counts in the S. aureus infected animals (18475 ± 685/µl; 
n=12; Fig 4.2.2) were significantly elevated two days after infection compared to 
noninfected control animals (9000 ± 305/µl; n=11; P < 0.001; Fig 4.2.2). Afterwards, 
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leukocyte counts decreased in the S. aureus infected animals but, remained 
significantly elevated compared to the control animals until day 20 pi (12457 ± 1219/µl 
versus 8583 ± 936/µl, P = 0.03; Fig 4.2.2). This increase in leukocyte counts in animals 
after S. aureus infection confirmed a strong chronic systemic inflammation.  
4.2.2: Infection with S. aureus enhanced lymphocyte counts in peripheral blood 
Flow cytometry was performed to detect the lymphocyte counts in peripheral blood on 
day 4 post immunization (pi) (directly prior to infection) and day 6 post immunization 
(corresponding to day 2 after the infection).  
B-cell counts were significantly increased in the S. aureus infected group (67 ± 
10.55%; P = 0.002; Fig 4.2.3 B, D; E; n=4) on day 6 pi compared to day 4 pi. In 
contrast, no significant change in B-cell counts was observed in noninfected animals on 
day 6 pi compared to day 4 pi (Fig 4.2.3 A, C; E). T-cell counts increased significantly in 
both the groups on day 6 pi compared to day 4 pi, however, the increase was more 
prominent in infected than in noninfected animals (117 ± 19.38% (Fig 4.2.3 D, F; versus 
45 ± 8.32%; P = 0.013; Fig 4.2.3 C; F; n=4).  
Subsequently, T cell subpopulations were also counted and we observed a 
significant increase in Th- and Tc-cell count in the animals infected with S. aureus on 
day 6 pi compared to day 4 pi (Fig 4.2.3 G, H). However, the Th-cell count was also 
increased significantly in the control group (Fig 4.2.3 G) and showed an increasing trend 
in Tc-cell counts (Fig 4.2.3 H). Moreover, CD134 (Ox40) an activation marker for T-cells 
counts showed an increasing trend in both the infected and noninfected group (Fig 4.2.3 
I) on day 6 pi corresponding to day 2 post infection. These results indicated that 
infection with S. aureus induces both B-cell and T-cell response in the periphery without 









Fig 4.2.3: Flow cytometry: Flow cytometry was performed in peripheral blood to assess 
lymphocyte populations in animals infected with S. aureus (B, day 4; D, day 6) and noninfected 
control group (A, day 4; C, day 6) on day 4 post immunization (prior to infection) and on day 6 
post immunization (corresponding to day 2 post infection). E and F represent the quantitative 
data for B- and T-cell counts, which were substantially increased in infected animals two days 
after infection. G, H and I represent the quantitative data for Th-, Tc- and the number of 
activated T-cells on day 6 compared to day 4 post immunization. 
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4.2.3: Chronic S. aureus infection and disease activity in MOG-EAE 
There is a possibility that infection may interfere with the immunization process. 
Therefore to avoid interference with the initiation of the autoimmune response animals 
were infected with S. aureus on day 4 after immunization  
 
Fig 4.2.4: Clinical score: Infection with S. aureus on day 4 pi prevented disease onset in MOG-
EAE. Data presented as means ± S.E.M. of the daily score.  
Around day 13 after immunization, 6 of the 14 placebo-infected animals developed 
clinical symptoms while infection with S. aureus prevented the clinical manifestation of 
EAE in all the infected animals. At the end of the experiment the mean cumulative score 
differed significantly between the group infected with S. aureus and the respective 
control group (no score vs 0.89 ± 0.4; P = 0.047; Fig 4.2.4). 
4.2.4:  Effect of S. aureus infection on neurodegeneration 
At day 8 of clinical disease or at day 21 after immunization in the absence of manifest 
disease, we determined the extent of demyelination of the optic nerves (ONs) by Luxol 
Fast Blue staining. Additionally, we performed immunohistochemistry for ED1 
macrophages/microglia and CD3+ T-lymphocytes to assess the extent of inflammatory 
infiltration. The chronic axonal damage was assessed by Bielschowsky’s silver 
impregnation. For each staining, ON cross sections of three different levels were 
evaluated. 




Fig 4.2.5: Optic nerve (ON) histopathology: A and B: Representative Luxol Fast Blue-stained 
cross sections of ONs of a wild-type S. aureus infected rat (A) showed only small areas of 
demyelination, with mainly intact myelin (blue) ; in contrast, a  from a noninfected control animal 
(B) showed extensively demyelinated areas (purple). C and D: Representative examples of the 
substantially higher number of ED1 macrophages / activated microglia detected in the ON of a 
noninfected control animal (D), compared with an animal infected with wild-type S. aureus (C). E 
and F: representative images for CD3-positive T-Lymphocyte counts, which were noted higher 
in the optic nerve of the animals from the control group (F) whereas CD3-positive cells were 
hardly present in the optic nerve of the group infected with bacteria (E). I, J, and K represent the 
quantitative data for demyelination, ED1 score and CD3-positive cells respectively. Bar length = 
100µm. 
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In the animals infected with the S. aureus wild-type strain we observed significantly less 
demyelination in ON cross sections (28.08 ± 7.94%; Fig 4.2.5 A, I; n=16) compared to 
noninfected control animals (67.41 ± 8.17%; P = 0.0011; Fig 4.2.5 B, I; n=14). Analysis 
of inflammatory infiltrates with ED1 staining revealed a substantially lower infiltration by 
macrophages and activated microglia in the infected group (1.22 ± 0.33; Fig 4.2.5 C, J; 
n=16) compared to the control group (3.41 ± 0.35; P < 0.001; Fig 4.2.5 D, J; n=14). 
Quantification of CD3+ cells revealed that only the minority of infiltrating cells were CD3+ 
T-lymphocytes. At day 21 after immunization, numbers of CD3+
 
Fig 4.2.6: Axonal loss and RGCs counts: Representative Bielschowsky’s silver impregnation 
of ON cross sections revealed a higher density of axons on EAE day 8 in wild-type infected 
animals (A) compared to noninfected control animals (B). C; shows the quantitative data for 
axonal loss between the group of animal infected with S. aureus and the noninfected group. 
Retrogradely labeled RGCs counting reveled a higher number of RGCs in the S. aureus 
infected group (D). Bar length = 20 µm. 
 cells were found to be 
significantly lower in the S. aureus infected group (10.09 ± 2.88/mm²; Fig 4.2.5 E, K; 
n=16) in comparison to the noninfected control group (34.46 ± 6.39/mm²; P < 0.001; Fig 
4.2.5 F, K; n=14). 
Using Bielschowky´s silver impregnation we observed a higher axonal density in S. 
aureus infected animals (129700 ± 14580/mm²; Fig 4.2.6: A, C; n=16) compared to 
                                                                                                                                        RESULTS 
52 
 
noninfected control animals (51260 ± 12810/mm²; P < 0.001; Fig 4.2.6: B, C; n=14). To 
evaluate the impact of infection on neurodegeneration, numbers of surviving RGCs, the 
neurons that form the axons of the ON, were counted on day 8 of MOG-EAE. 
Previously, we have shown that in healthy BN rats sham-immunized with complete 
Freund´s adjuvant (CFA), 2730 ± 145 RGCs/mm² were detectable (mean ± SEM; n=8) 
(Meyer et al., 2001). In our present study, the mean RGC density in noninfected control 
animals at day 8 of MOG-EAE dropped to 1085 ± 85.7/mm² (Fig 4.2.6: D, n=14). In 
contrast, the RGCs density of infected animals was significantly higher (1449 ± 
64.60/mm², P = 0.002; Fig 4.2.6: D, n=20). 
The results from clinical studies indicated a protective effect of S. aureus 
infection on course of disease and at the same time S. aureus infection also improved 
neuropathological damaged induced by MOG-immunization by reducing anti-
inflammatory activity in the CNS. 
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4.3: Effect of Eap-deficient strain of S. aureus on EAE  
These results were surprising because, despite of a strong systemic inflammation 
induced by locally applied chronic S. aureus infection the animal did not show any 
clinical sign of EAE and showed reduction in number of inflammatory infiltrate in the 
optic nerve.  
It is well known that S. aureus secrete various factors which could exert an anti-
inflammatory effect during the infection. An extracellular adhesion protein secreted by 
this bacterium has anti-inflammatory property which has been found to be present in 
97.9% of clinical isolates (Hussian et al., 2001). Furthermore, anti-inflammatory effect of 
Eap secreted by S. aureus was demonstrated in chronic infections as well as in 
autoimmune disease models (Chavakis et al., 2002; Lee et al., 2002; Wang et al., 
2010). Therefore, we hypothesize that this protein to be responsible for the protective 
effect of S. aureus infection in EAE. To prove our hypothesis a second set of 
experiments was performed by including a group of animals infected with S. aureus 
strain deficient for Eap (AH12), which was an isogenic mutant of wild-type Newmen 
strain of S. aureus (ATCC 25904). 
4.3.1 Infection with S. aureus strain deficient for Eap and systemic inflammation  
In this experiment leukocyte counts were significantly elevated two days after infection 
in the animals infected with  a wild-type strain (17236 ± 742/µl; n=11; P < 0.001) and in 
the animals infected with an Eap-deficient strain (18575 ± 585/µl; n=10; P < 0.001) in 
contrast to the control group (9940 ± 527/µl; n=5). Moreover, TCF plating revealed the 
presence and absence of bacteria in tissue cage fluid of both the infected and control 
group respectively. Although the exact determination of bacterial count was not possible 
due to the semi-solid consistency of TCF obtained from both the infected groups. 
However, we did not observe any significant difference between the leukocyte counts 
from both the infection groups at any time point during the whole course of the 
experiment. These results indicated that the level of infection in both the bacterial 
infected groups was similar and that should not be a region for any discrepancies in the 
results obtained from the group of animals infected with either wild-type S.aureus 
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(ATCC 25904) or the animals infected with strain of the S. aureus deficient for Eap 
(AH12).  
 
Fig 4.3.1: Blood leukocyte counts: - Leukocyte counts performed in peripheral blood of 
animals infected with, Eap-deficient bacterium (Mutant), S. aureus wild-type bacterium (Wild-
type), and in saline injected myelin oligodendrocyte glycoprotein- (MOG) immunized animals 
(Control). The leukocyte counts were found to be significantly higher in both the infected group 2 
days after the infection. Data are presented as means ± SEM of all animals from each group. 
4.3.2: Infection with S. aureus and cytokines release in the systemic circulation 
In spite of Eap exhibit anti-inflammatory activity during infections and do not resemble 
the structural homology to superantigens (Haggar et. al., 2010), the binding of Eap to 
ICAM-1 on the surface of peripheral blood mononucleocytes triggers the release of pro-
inflammatory cytokines like TNF-α and IL-6 (Scriba et.al., 2008). However, 
determinations of cytokines from in vivo is rather difficult, but in this experiment 
concentration of 12 cytokines were measured simultaneously by using the Bioplex 200-
system in the serum samples collected at the end of the experiment. These results 
indicated that animals infected with the wild-type strain of S. aureus showed a 
significantly higher level of IFN-gamma, IL-6 (Fig 4.3.2). The quantitative levels of the 
cytokines measured in the serum samples are indicated in table 4.3.1. 





Fig 4.3.2: Luminex assays. Luminex detection assays indicated a significant increase of IL-6 
(F) and IFN-gamma (J) and in the blood of animals infected with S. aureus wild-type strain. 
More detailed, levels of IFN-gamma (Fig 4.3.2 J) was significantly increased in animals 
infected with the wild-type bacteria (411.4 ± 28.37 pg/ml) compared to animals infected 
with the Eap-deficient strain (303.9 ± 39.08 pg/ml; P = 0.035) and compared to 
noninfected control animals (284.9 ± 46.49 pg/ml; P = 0.029). Serum levels of IL-6 (Fig 
4.3.2 F) were also significantly elevated in the group infected with the wild-type S. 
aureus bacterium (926.6 ± 57.27 pg/ml) compared to the group infected with the Eap-
deficient bacterium (704.4 ± 75.48 pg/ml; P = 0.028) and the control group (668.7 ± 
119.1 pg/ml; P = 0.042). A tendency towards higher serum levels of TNF-α (Fig 4.3.2 K) 
and IL-13, an anti-inflammatory cytokine (Fig 4.3.2 I) was observed in the animals 
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infected with wild-type S. aureus bacteria compared to the group infected with Eap-
deficient S. aureus and the noninfected control group.  






IL1 -alpha 192.3 ± 12.70 165.5 ± 18.54 150.7 ± 23.82 
IL-1 beta 2025 ± 125.9 1827 ± 256.3 2012 ± 308.1 
IL-2 181.7 ± 19.44 245.7 ± 37.52 166.1 ± 19.57 
IL-4 258.6 ± 18.98 284.1 ± 53.28 210.6 ± 36.45 
IL-5 599.9 ± 29.66 519.9 ± 42.49 560.6 ± 94.28 
IL-6 926.6 ± 57.27 704.4 ± 75.48 668.7 ± 119.1 
IL-10 1348 ± 92.67 1239 ± 117.0 1290 ± 191.8 
IL-12 483.3 ± 60.40 500.9 ± 122.7 293.4 ± 43.98 
IL-13 254.8 ± 18.78 204.4 ± 31.00 170.2 ± 23.76 
TNF- alpha 330.7 ± 82.96 233.2 ± 51.44 169.9 ± 30.89 
IFN- gamma 411.4 ± 28.37 303.9 ± 39.08 284.9 ± 46.49 
GM- CSF 219.4 ± 19.10 201.2 ± 28.80 167.1 ± 37.49 
Table 4.3.1: Quantitative data for cytokine analysis: Table represents the quantity of 
cytokine concentration in the serum sample collected at the end of the experiment.  
Although the results were not significant but the group of animals infected with Eap-
deficient bacteria also showed a tendency towards higher of proinflammatory cytokines 
such as IL2 and IL12. Therefore these data showed that the pro- and anti-inflammatory 
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activity in the periphery is ongoing together, indicating that the variation in the cytokines 
profile could have influenced on disease severity. 
4.3.3: S. aureus infection and its impact on clinical manifestation of the disease 
Concerning the clinical manifestation of the disease, no clinical signs of EAE were 
observed in the group infected with S. aureus wild-type as well as in the group infected 
with the Eap-deficient strain. In contrast, noninfected control animals were severely 
affected with an EAE score of 2.4 ± 0.36 (n=5; P < 0.001) at the end of the experiment. 
Although no clinical signs of EAE were observed in the group infected with S. aureus or 
in the group infected with the Eap-deficient strain of S. aureus, animals of the group 
infected with Eap-deficient S. aureus displayed higher level of histopathological 
abnormalities (see below). 
 
Fig 4.3.3: Clinical manifestation of disease: Clinical manifestation of disease was abolished 
completely in animals infected with S. aureus bacteria. 
4.3.4: Neuropathological damage and RGCs survival after Infection with Eap-
deficient strain of S. aureus 
Histopathilogical analysis performed on the optic nerve s revealed that the protective 
effect of wild-type S. aureus infection on optic neuritis is reduced in the group infected 
with respective Eap-deficient strain.  
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In more detailed, we observed significantly less demyelination (Fig 4.3.4 A) in 
wild-type S. aureus infected animals (22.77 ± 8.46%; n=11) in comparison to both the 
animals groups infected either with S. aureus deficient for Eap (53.53 ± 10.56%; P = 
0.027; n=10) or the control animals (100 ± 0%; P < 0.001; n=4). Accordingly, the extent 
of inflammation accessed by ED1 staining (Fig 4.3.4 B) was significantly lower in the 
group infected with wild-type S. aureus bacteria (1.24 ± 0.39; n=11) in comparison to 
the group infected with Eap-deficient bacteria (2.73 ± 0.40; P = 0.012; n=10) and the 
noninfected control group (4.66 ± 0.15; P < 0.001; n=4). 
 
Fig 4.3.4: Optic nerve (ON) histopathology after infection with wild type S. aureus along 
with the strain deficient for Eap: The positive effect of S. aureus on optic neuritis was 
reverted in the Eap-deficient strain. A, B and C represents the quantitative data for extent of 
demyelination, ED1 score and CD3+ cells respectively.   
CD3+ T-Lymphocyte counts revealed significantly lower numbers of CD3+ cells (Fig 4.3.4 
C) in animals infected with wild-type S. aureus (7.6 ± 3.75/mm²; n=11) in comparison to 
the animals infected with Eap-deficient bacteria (39.81± 10.37/mm²; P = 0.004; n=10) 
and the control group (55.2 ± 25.8/mm²; P = 0.007; n=4). No significant difference was 
observed in CD3+
Bielschowsky´s silver impregnation was performed to assess the axonal 
pathology of the optic nerve (Fig 4.3.5 A) and revealed that the animals infected with 
wild-type bacteria showed a higher number of axonal counts (173500 ± 18220/mm²; 
 cell counts between the animals infected with Eap-deficient S. aureus 
bacteria and the noninfected control group (P = 0.5).  
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n=11) in comparison to the group infected with Eap-deficient bacteria (73953 ± 




Fig 4.3.5: Axonal loss and RGCs count after infection with wild type S. aureus along with 
the strain deficient for Eap (mutant): Bielschowsky’s silver impregnation (A) of ON cross 
sections revealed a significantly higher density of axons on EAE day 8 in wild-type infected 
animals. Retrogradely labeled RGCs counting (B) showed a higher number of RGCs in the 
group of animals infected with wild-type S. aureus bacterium. 
The RGCs counts were performed on retinal flat mount which revealed a higher 
RGC density in the animal group infected with the wild-type strain (1447 ± 66/mm²) 
compared to animals infected with the Eap-deficient strain (1001 ± 65/mm²; P < 0.001; 
Fig 4.3.5) and the noninfected control group (810 ± 52/mm², P < 0.001; Fig 4.3.5). 
Although the infection with Eap-deficient S. aureus bacterium has a protective 
effect on the clinical course of disease but these results also indicated that the infection 
with wild-type bacterium is more protective in terms of optic nerve injury and RGCs 
counts compared to the animals infected with bacterium deficient for Eap or the control 
animals. 




There is an extensive clinical literature describing the effect of infections on clinical 
course of MS, mostly on exacerbation of the disease course, but in some instances 
reducing relapses especially in case of parasitic infection (Correale and Farez, 2011; 
Correale and Farez, 2013; Fleming and Cook, 2006). In the present work we 
investigated the extent to which an acute infection with E. coli and chronic infection with 
S. aureus influences the course and severity of MOG induced EAE in female Brown 
Norway rats.  
5.1: Infection and MS 
There is a growing body of evidence that the progression of MS is influenced by 
systemic infection caused by bacteria or viruses. Moreover, components associated 
with certain bacteria and viruses have been shown to be a potential modifier in the 
progression of autoimmune diseases (Hamada et al., 1989; Nogai et al., 2005; Soos et 
al., 1995; Xie et al., 2006). However, only few studies have investigated the direct 
impact of infection with viable bacteria in the animal models of MS, which reflect more 
likely a clinical situation. The results of MRI on the influence of peripheral infection and 
the number of contrast-enhancing MS lesions as a marker of disease activity are 
inconsistent (Edwards et al., 1998; Kalkers et al., 2002). Moreover, reliable markers for 
neurodegeneration in MS patients do not exist. For this reason, much of the knowledge 
about the interaction of systemic infection and autoimmunity in MS is derived from 
studies in EAE models. Previous studies in EAE models mainly focused on analyzing 
the clinical course of the disease. Furthermore, in most experiments solely bacterial 
compounds were used to induce systemic inflammation (e.g. LPS, enterotoxins) 
(Moreno et al., 2011; Schiffenbauer et al., 1993; Soos et al., 1995) instead of whole 
viable bacteria, therefore these studies showed the limited value concerning the 
reflection of the clinical situation in MS-patients. 
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5.1.1: Acute infection with E. coli and EAE  
Clinical as well as experimental data indicated that the preclinical phase prior to the 
disease manifestation to be a period with the highest susceptibility to infections 
(Herrmann et al., 2006). However, during the disease course of MS, infections with 
common bacteria are also observed, which could have the potential to modulate the 
disease severity. Therefore, to elucidate the impact of infections in our study, two 
different infection time points were selected. In the first group, animals were infected at 
day 7 post immunization corresponding to the preclinical phase of the disease. 
Furthermore, to reflect the clinical situation a second group of animals was infected on 
day of clinical onset of disease. To increase the survival of animals after the infection, 
they were treated with ceftriaxone, a beta lactam antibiotic used for the cure of bacterial 
infection. The effect of beta lactam antibiotic in an animal model of MS remains 
controversial. In the study of Nico Melzer and coworkers, it was shown that the 
ceftriaxone treatment ameliorated the clinical course of MOG-induced EAE in mice by 
modulating cellular antigen-presentation and impairment of antigen-specific T-cell 
migration into the CNS (Melzer et al., 2008). In contrast to this finding Felix Mor and 
colleagues showed that adoptive transfer of BP10 cell line incubated with ceftriaxone 
shown more severe EAE symptoms (Mor and Cohen, 2013). Moreover, they also 
showed that cefuroxime, another beta lactam antibiotic enhanced adjuvant-induced 
arthritis and experimental autoimmune encephalomyelitis (EAE) in both active and 
passive forms. However, to rule out the side effect of ceftriaxone in our study all the 
animals from infected and noninfected group was treated with ceftriaxone during the 
experimental phase of disease.  
Viral and bacterial infections can aggravate the disease symptoms in MS patients 
(Buljevac et al., 2002). Moreover, in the previous experimental studies in EAE it has 
been shown that the, bacteria like Chlamydia pneumoniae and Streptococcus 
pneumoniae could exacerbate the disease symptoms (Du et al., 2002; Herrmann et al., 
2006). Here, in our study, in spite of a systemic infection with E. coli in the preclinical 
phase of disease induced weight loss in EAE animals considering as a sign of general 
sickness behavior, it has no influence neither on the time point of onset of clinical EAE 
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symptoms nor on the severity of the disease. Moreover, to reflect the clinical situation, 
we infected the animals on the clinical onset of EAE. Despite the presence of bacteria in 
the systemic circulation of E. coli infected animals next days after clinical onset of 
disease it did not influence the disease severity. Further, histopathological analysis 
performed on the optic nerves of animals did not reveal any significant increase in 
inflammatory infiltrates in the animals infected with E. coli either on day 7 post 
immunization or on day 1 EAE compared the respective control. Further, in this study, 
we did not observe any significant difference in other histopathological correlates like 
demyelination and axonal counts on the optic nerves in the group infected with E. coli 
compared to the control. 
Results obtained from the acute infection with E. coli in this animal model, did not 
reflect the previous findings, those which were performed with the bacterial components 
and induce a robust, but short lasting systemic inflammation. It has been shown that E. 
coli infection increases the permeability of the BBB during sepsis, but unable to cross 
the BBB (Tsao et al., 2001). Moreover, it has also been suggested that infection of CNS 
is necessary for worsening of EAE (Du et al., 2002). These experimental data could 
possibly explain the discrepancies in our finding compared to the previous experimental 
studies. However, other possible reasons for such discrepancies in our result might be 
due to balance between Th1/Th2 cytokine profile, molecular mimicry and the role of Toll 
like receptors (TLRs). These finding also suggested that the kind of micro-organism also 
has influence on exacerbation of EAE relapse and their histopathological changes. 
5.1.2: Chronic infection model  
Foreign body infections are characterized by the presence of adherent bacteria on the 
surface of the synthetic prosthetic materials for a very long time and these bacteria 
supposed to escape host dependent phagocytic mechanisms. S. aureus is a common 
pathogen in both hospital- and community-associated infections (Grady and Cullen, 
2003) and cause serious complications in prostheses by formation of biofilm and 
developing tolerance towards an antibiotic treatment (Murillo et al., 2006). S. aureus 
contains or secretes around 200 products, which may interfere with immune-
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inflammatory reaction and can confer virulence of the host. Moreover, the involvement 
of some of the bacterial components, isolated from S. aureus, in the modulation of EAE 
was demonstrated in previous experimental studies (Schiffenbauer et al., 1993; Soos et 
al., 1995; Xie et al., 2006). Therefore, these observations indicated, S. aureus to be the 
ideal microorganism to study the effect of chronic infection in vivo. Lucet and co-workers 
established an experimental model of chronic foreign body infection by inoculating 105 - 
106 CFU of S. aureus in the implanted tissue cages containing two PMMA cover slips in 
Wister rat (Lucet et al., 1990). 
However, in our study tissue cages implant with PMMA cover slips was unable to 
induce the chronic infection even with a high inoculum dosage of 109
5.1.3: Chronic infection with S. aureus, induces systemic inflammation 
 CFU of S. aureus 
in BN rat. To overcome this problem semi-solid agar, an excellent medium for the 
growth of bacteria, was injected directly into the implanted tissue cages of the animals 
prior to infection. That further leads to a persistent chronic infection in this animal model. 
The advantage of this chronic infection model is that, it induces mild infection and even 
without antibiotic treatment, it does not lead to death of the animal. A major advantage 
of agar injection into the implant was that, it reduces the inoculum dosage of S. aureus 
to induce the chronic infection, which allow us to stabilize the implant in the body of the 
animals for longer time duration. 
Infection with bacteria induces the sign of sickness behavior, which reflects in the form 
of weight loss (Perry, 2010). Interestingly, animals infected with S. aureus did not show 
any weight loss after the infection. Moreover, during the course of the experiment we 
did not observe the presence of bacteria in the peripheral blood of animals, when plated 
on the blood agar plate. However, at the end of the experiments, TCF obtained from the 
animals infected with S. aureus showed a high number of bacterial counts (S. aureus) 
on the blood agar plate, whereas no bacterial growth was observed in TCF obtained 
from noninfected control animals. The data obtained from TCF, obtained at the end of 
the experiments, plated on the blood agar plate confirmed the persistent chronic 
infection in the tissue cage of the animals. Moreover, leukocyte counts in the peripheral 
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blood from the S. aureus infected animals showed a significant increase in the blood 
leukocyte counts, 2 days after the local application of the bacteria in the tissue cage. 
Further, flow-cytometric analysis of the peripheral blood circulation also showed a 
significant increase in the population of B- and T-cell count in the animals infected with 
S. aureus. Furthermore, the flow cytometric analysis also indicated a more pronounced 
increase in the T-cell subpopulation 2 days after the infection, compared to the control. 
These results confirm that a chronic infection with S. aureus leads to a very strong 
systemic inflammatory response in the peripheral blood circulation of the animals. 
It has been shown that after the infection, Infectious agents can expand the pool 
of host’s immune cells, which also includes auto-reactive T-cells in EAE and thus can 
contribute to the disease progression (Du et al., 2002; Nogai et al., 2005; Visser et al., 
2005). Thus we hypothesized that due to increase in leukocyte counts and a substantial 
increase of B-, T- and subpopulation of T-cell in peripheral blood after the infection, it 
will lead to more severe damage to the brain tissue and possibly could exacerbate the 
symptoms of EAE. Unexpectedly, the infection with S. aureus prevented the 
development of clinical EAE. Moreover, it significantly decreased the extent of 
inflammatory infiltrates and demyelination of the optic nerve. However, these results can 
be explained on the basis of hygiene hypothesis which states that infections protect 
rather than induce/accelerate autoimmune diseases like MS (Bach, 2002). The hygiene 
hypothesis proved to be protective in several clinical and experimental studies (Correale 
and Farez, 2011). Moreover, hygiene hypothesis also state that due to hyper-activation 
of auto-reactive cells with further activation leads to cell death and may reduce the 
number of aggressive cell number. Moreover, the competitive mechanisms between the 
infectious agent and the body own immune cells for the antigen binding over MHC 
molecules and antigen processing by phagocytic cells could also play an important role 
in this protective function. In the previous finding it has been shown that the induction of 
superantigens produced by different infectious agents can exacerbate the EAE 
(Schiffenbauer et al., 1993). However, these findings could have a different prospective 
as well. It is well known that after the antigen presentation on MHC grove it leads to the 
activation of specific T-cell population bearing particular T-cell-receptor in variable 
regions of the beta chain. However, the presence of superantigen induces polyclonal T-
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cell activation (Fraser and Proft, 2008). Hence, in my opinion of superantigen might 
cause a reduction of activated T-cell number expressing a particular TCR by modulation 
in the variable region of beta chain (Correale and Farez, 2011).  
5.1.4: Chronic infection with S. aureus and cytokine release  
It is well known fact that infection induces cytokine release in the periphery, which is 
crucial for fighting against infections. However, sometimes they can become 
dysregulated during inflammation, trauma, and sepsis (Dinarello, 2000). In multiple 
sclerosis how the regulations of different cytokine takes place are not clearly known. 
Experimental studies indicated that in EAE, the release of pro-inflammatory cytokines 
worsen the disease, whereas anti-inflammatory cytokines reduce inflammation and 
promote healing. Moreover, it has been shown that the pro-inflammatory cytokines like 
IL-1, IL-6, IL-12, IL-17, IL-23, TNF-α, and IFN-gamma seems to increase the severity of 
the disease in EAE (Komiyama et al., 2006; Langrish et al., 2005; Samoilova et al., 
1998). In contrast to this several experimental studies indicated the protective role of 
IFN-gamma and TNF-α in EAE (Furlan et al., 2001; Willenborg et al., 1996; Zhang et al., 
2012). 
In spite of anti-inflammatory activity of Eap during infection, in our study, we 
detected a significant increase in the level of the IL-6 and IFN-gamma levels at the end 
of the experiment in the group infected with S. aureus wild-type strains. However, such 
a pro-inflammatory cytokine pattern was not detected in animals infected with the Eap-
deficient strain. Our findings correspond well to in vitro data showing increased 
secretion of IL-6 and TNF-α in murine cells and in human blood samples after 
stimulation with Eap (Edwards et al., 2012; Scriba et al., 2008) and indicate pro-
inflammatory properties of this protein in the systemic circulation. However, Scriba and 
coworkers also showed that this pro-inflammatory cytokine release is taking place 
through monocytes and macrophages but not by T-cell populations. Intriguingly, in spite 
of ongoing inflammation in the periphery the infection with S. aureus prevented the 
onset of clinical EAE symptoms and decreased the severity of autoimmune optic 
neuritis. According to our hypothesis secretion of Eap blocks the migration of 
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inflammatory cells into the CNS, which in turns protects the integrity of the BBB. 
However, less infiltration of T- and B-cells in the animals infected with S. aureus restrict 
the innate release of pro-inflammatory cytokines from these cells into the CNS. When 
the BBB is intact, the majority of the blood borne cytokines enters into the CNS by the 
saturable transport system (Banks, 2005; Banks et al., 1991), which facilitates the 
selective movement these cytokines across the BBB. However, during EAE the 
alteration in the permeability of the BBB allows an unrestricted movement of these 
cytokines into the CNS, which probably not the case in the animals infected with S. 
aureus. This could be a possible reason why ongoing inflammation in the periphery has 
no deleterious effect on the course of this disease. 
5.1.5:  The role of adhesion molecules in transendothelial migration 
The entry of leukocytes into the CNS is considered as an early event in MS. That 
includes the involvement of cytokines, chemokines and adhesion molecules expressed 
by both the activated endothelium and the immune cells, which further leads to the 
breakdown of the BBB and inflammation of the CNS. The relevance of VLA-4 - VCAM-1 
for migration of lymphocytes across the BBB during EAE has been shown in several 
experimental studies (Archelos et al., 1993; Gordon et al., 1995; Yednock et al., 1992). 
Moreover, several genetics studies also indicated the relevance of adhesion molecules 
in the susceptibility of the disease (Damotte et al., 2014). The co-ordinated sequential 
events of inflammatory cells migration into the CNS, especially, involve the VLA-4 - 
VCAM-1 and the LFA-1 - ICAM-1 adhesion systems (Engelhardt and Wolburg, 2004; 
Laschinger and Engelhardt, 2000; Lee and Imhof, 2008; Wittchen, 2009). However, 
there is increasing evidence that both systems may have a distinct contribution in the 
recruitment of myelin activated T-cells. Experimental studies also indicated the organ 
specific expression of such molecules on their endothelium during autoimmune 
inflammation. Moreover, the subtype of T-cells that are involved in the pathology may 
vary in patients (Bitsch and Bruck, 2002; Metz et al., 2014). It has been shown, that 
Th1- and Th17-cells filtration in the spinal cord is dependent on a VCAM-VLA-4 
interaction (Rothhammer et al., 2011). In contrast to this finding Bharadwaj and 
coworkers showed that the vascular endothelial migration of Th1- and Th17-cells was 
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mediated by ICAM instead of VCAM expression (Bharadwaj et al., 2013). Hence it can 
be speculated from a previous finding that different subtypes of activated T-cells will be 
recruited on various adhesion molecules and crosses the BBB.  
Humanized monoclonal antibody natalizumab is in therapeutic use for MS. In a 
clinical study it was observed that natalizumab treatment reduced the MRI activity by 
92%, which showed the highest efficacy for any drugs available for treatment of MS 
(Miller et al., 2007; Polman et al., 2006). Natalizumab treatment targets the a4-integrin 
molecule, a component of the VLA-4 present of lymphocytes thus prevents the 
interaction with VCAM found on endothelial surfaces and subsequently blocks the 
migration of the lymphocytes to the CNS, which resulted in the reduction of the 
inflammation in the CNS and disease severity of the disease. However, some patients 
do not respond to the natalizumab treatment, especially in patients with progressive 
forms of MS. This clearly indicates the heterogeneity of mechanism involve in the 
disease pathogenesis of MS. Another concerning factor for natalizumab treatment is the 
incidence of PML (2.1/1000 patients) which increases with the length of treatment 
(Bloomgren et al., 2012; Clifford et al., 2010). Moreover, the patient becomes more 
susceptible if they were treated with an immunosuppressant before receiving 
natalizumab (Kappos et al., 2011). In contrast to the VLA-4 - VCAM-1 interaction 
several studies indicated the role of ICAM in pathogenesis of MS (Bullard et al., 2007; 
Damotte et al., 2014; Steiner et al., 2010).  Furthermore, the expression of ICAM-1 has 
been shown to be up-regulated in MS. Eventually there is no current therapy targeting 
the LFA-1 - ICAM-1 adhesion pathway. 
Staphylococcal enterotoxins (SEs) are one member of a unique group of 
molecules called super-antigens which could induce a very strong immune response in 
the animals. Moreover, it has been also shown that super antigens may trigger EAE by 
stimulation of autoreactive T-cells from the variable region of beta chain (Schiffenbauer 
et al., 1993; Soos et al., 1995). In contrast to this, S. aureus also secrete several anti-
inflammatory and anti-adhesive factors that may interfere with every step of 
inflammatory cells recruitment of the host (Chavakis et al., 2007) and help them for an 
efficient colonization within the host (Chavakis et al., 2005; Foster and Hook, 1998).  
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S. aureus secrete a group of anti-adhesive protein consist of 5 different structurally 
unrelated secreted adhesion molecule named as “secretable expanded repertoire 
adhesive molecules” (SERAM), and one of them is Eap (Chavakis et al., 2007). Eap, 
also called as Map, ''MHC class II analogous protein’’, which has been shown to be 
present in 97% of clinical isolates (Harraghy et al., 2003). The Eap not only help 
bacteria to get adhere but also interferes with host defense mechanisms. It has been 
shown that Eap specifically interacts with endothelial ICAM-1 and inhibit the recruitment 
of neutrophil at the site of infection. Furthermore, Eap also interfere with T-cell migration 
by blocking the interaction between LFA-1 and ICAM-1 (Athanasopoulos et al., 2006; 
Chavakis et al., 2002; Haggar et al., 2004). Moreover, an anti-inflammatory effect of 
Eap in autoimmune diseases has been found in EAE and an animal model of psoriasis 
(Wang et al., 2010; Xie et al., 2006).  
Despite of a significant increase in T-cells count in the animals infected with S. aureus it 
showed a significantly less infiltration of T-cells on the optic nerve of the animals. These 
findings strongly suggested the involvement of a factor which, probably involved in the 
trans-migration of myelin activated T-cells across the BBB. Based on these 
observations, we hypothesized that the anti-inflammatory effects of S. aureus infection 
in MOG-EAE are mediated through the secretion of Eap. We infected the animals with 
the S. aureus strain deficient for Eap. In our study, the infection with the Eap-deficient S. 
aureus strain led to increased inflammation, demyelination and axonal damage in the 
optic nerve compared to the animals infected with the wild-type S. aureus strain. 
However, histopathological analysis of the optic nerve revealed that the anti-
inflammatory property of S. aureus infection was not completely abolished by lacking 
Eap. Moreover, the infection with the Eap-deficient strain prevented the clinical 
manifestation of the disease, indicating that additional mechanisms are involved in the 
anti-inflammatory effects of S. aureus. Given the importance of ICAM-1 antagonism in 
different autoimmune diseases (Kaneider et al., 2006), Eap is considered to be the most 
potent factor for inhibition of T-cell migration into the CNS. This hypothesis is supported 
by our histopahological evaluations revealing a substantial decrease of lymphocyte 
count in inflammatory infiltrates of the optic nerve in wild-type S. aureus infected 
animals. 
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5.2: Infection and neurodegeneration  
Epidemiological data implicated both genetic and environmental factors in the etiology 
of MS. The association of systemic infection and risk of MS relapse has been proposed 
on the basis of epidemiological data (Handel et al., 2010) from several clinical studies 
(Correale et al., 2006; Sibley et al., 1985). However, whether the infection leads to the 
increased neurodegeneration, a major hallmark of disability in MS patients is not fully 
understood. 
Microglials are the innate immune cells of the brain and plays a very important 
role in the maintenance of the microenvironment of the CNS. In the presence of external 
stimulus these cells can become activated which is crucial for host defense mechanism. 
However, over-activation of microglia may cause neurotoxicity (McGeer et al., 2005; 
Polazzi and Contestabile, 2002). Peripheral inflammation, which leads to the activation 
of Microglial cells is a common phenomenon of several neurodegenerative diseases like 
Parkinson's disease, Alzheimer's disease, Multiple sclerosis and Amyotrophic Lateral 
Sclerosis (Nguyen et al., 2002). It is now well established, that in chronic 
neurodegenerative diseases of the CNS, such as Parkinson and Alzheimer diseases 
the resident microglia are primed by prior pathology to respond more vigorously to 
inflammatory stimulation. In this context, the signals from systemic infection or 
inflammation lead to a switch of microglia/macrophages towards a pro-inflammatory 
phenotype (Cunningham, 2013; Perry et al., 2007) and this switch contributes to 
progression of neurodegeneration (Ferrari et al., 2006; Nguyen et al., 2004). 
The majority of studies on studying the interaction of systemic infection and 
autoimmunity have been performed on EAE animals using a single challenge with 
lipopolysaccharide (LPS), which is present on the outer membrane of Gram-negative 
bacteria. Systemic insult with LPS leads to a switch in the macrophage/microglia 
phenotype in the rat EAE model. This switch was accompanied by prolonged pro-
inflammatory response by releasing inducible nitric oxide synthase (iNOS) and 
expression of pro-inflammatory cytokines, which in turns lead to the more pronounced 
neuronal damage (Moreno et al., 2011). But whether these bacterial components (LPS, 
enterotoxins, or teichoic acid, etc.), which are commonly used to mimic the situation of 
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bacterial infections does have the similar effect on neurodegeneration is not clearly 
known. Thus, the systemic inflammation induced by bacterial infections has to be 
addressed, particularly within the experimental models of MS.  
Role of TLRs in infection and EAE have been studied which are expressed on several 
types of cells, including peripheral lymphocytes, microglia cells and neurons (Kawai and 
Akira, 2007). Extracellular leucine-rich repeat domains of these receptors have been 
shown to be involved in specific pathogen recognition (Akira et al., 2006). However, the 
cytoplasmic domain is involved in signaling pathways. Upon sensing ligands, 
recruitment of adaptor proteins (MyD88 except for TLR3) takes place which in turns 
initiate the signal transduction pathway and leading to activation of NF-κB and induced 
the production of pro-inflammatory cytokines like TNF-α, IL-6, and I L-1b etc. It is also 
observed that MyD88 pathway plays a crucial role in CNS infection and optic nerve 
injury (Zheng et al., 2012). In the previous study it has been shown that Chlamydia 
pneumoniae infection exacerbates EAE in mice. Moreover, from the mechanistic point 
of view Herrmann and coworkers showed that Streptococcus pneumoniae, a gram 
negative bacterium causes respiratory tract infection, can aggravate EAE via TLR2 
without affecting the level of pro-inflammatory cytokines and T-cell proliferation. 
However, in both of these studies there was no evidence for the neuronal cell loss. 
These animal studies indicate the role of systemic infection on CNS, but whether these 
infections lead to the more pronounced neurodegeneration is not clearly known. In this 
study, we address the impact of infection on neuronal damage after the infection in 
acute as well as in chronic Infectious conditions. In our study despite of presence of E. 
coli in the peripheral blood circulation 24 h after the infection we did not observe any 
significant difference in the loss of RGCs between the animals infected with E. coli and 
the control during clinical and preclinical phase of disease. However, the loss of RGCs 
showed a trend for more pronounced RGCs loss of in the animals infected on day 1 
EAE compare to its control. Thus, acute E. coli infection could possibly have long-term 
consequences in regards to neuronal degeneration. 
We know from previous study that neuro-inflammation caused by external 
stimulus, which leads to the activation of microglial cells is not always deleterious 
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(Glezer et al., 2006; Simard et al., 2006). However, in our study with the chronic 
infection model we infected the animals with S. aureus during the preclinical phase of 
disease, which induces a strong inflammatory response in the periphery showed by 
increased leukocyte counts. Surprisingly, we observed an increased neuronal survival in 
the animals infected with S. aureus compared to its control. These results indicated that 
the importance of BBB, that probably does not allow the inflammatory cells to enter into 
the CNS and induce the inflammatory signal across it. Moreover, by introducing Eap 
mutant strain in this study, we observed a higher neuronal survival in animals infected 
with wild-type bacterium compared to the animals infected with bacterium deficient for 
Eap. In our previous EAE studies with the same animal model, we observed that strong 
anti-inflammatory treatment is not always sufficient to prevent neurodegeneration (Diem 
et al., 2003; Maier et al., 2006; Rau et al., 2011). Even though we see a more neuronal 
survival in the animals infected with wild-type bacterium compared to the animals 
infected with bacterium deficient for Eap we cannot rule out a direct neuroprotective 
effect of Eap. Further studies are needed to clarify this issue. Nevertheless, by 
suppression of LFA-1 and ICAM-1 mediated transendothelial migration of immune cells 
into the CNS with consecutive neuroprotection, Eap has potential to serve as a new 
therapeutic for the treatment of MS. 
5.3: A clear distinction between the animal model of MS is important 
In the previous experimental studies it has been shown that the systemic inflammation 
induced by bacterial components lead to exacerbation of the disease course in EAE 
(Moreno et al., 2011; Schiffenbauer et al., 1993; Soos et al., 1995). Although in our 
studies we found that the inflammatory stimulus induce by a viable bacterium was more 
pronounced, it does not seem to have the similar effect as found in the previous finding 
performed by the use of solely bacterial components. Moreover, data from the acute 
infection model induced by E. coli also differed from the results obtained from the 
chronic infection model induced by the S. aureus. Nevertheless, the time point of 
infection as shown by Herrmann et al could also play determining role in the disease 
pathogenesis. From the previous and our current finding we conclude that the robust, 
but short lasting defined inflammatory stimulation induced by the bacterial components 
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like LPS or enterotoxins felt adequately to reproduce the full spectrum of inflammatory 
changes a real systemic infection (Remick and Ward, 2005). Therefore, this is important 
to draw a clear distinction between these models of systemic inflammation to study 
various autoimmune diseases like MS. 




To address the question how does the bacterial infections (acute and chronic) influence 
the severity of disease in an experimental model of MS, we investigated the extent to 
which an acute infection with E. coli  and chronic infection with S. aureus influences the 
disease course of MOG induced EAE in female Brown Norway rats. Moreover, we also 
investigated the effect of the acute and chronic bacterial infection on 
neurodegeneration. 
In the current study, viable E. coli infection in female BN rats did not influence the 
clinical course of disease in EAE. Moreover, we did not observe any significant 
histopathological changes, performed in the optic nerve s as well as on the survival of 
RGCs, in the group infected with E. coli compared to the control. Findings from these 
studies indicated that the systemic insult with bacterial components 
(Lipopolysaccharides, superantigens) do not reflect the true inflammatory conditions 
induced by a viable bacterial infection. Therefore this is important to draw a clear 
distinction between these two models of systemic inflammation. 
In contrast to the acute infection, chronic infection induced by inoculating S. 
aureus into the agar of the implanted tissue cage showed a chronic systemic 
inflammatory response with increased in T- and B-cell counts as well as systemic 
production of pro-inflammatory cytokines. Unexpectedly, the chronic infection with S. 
aureus prevented the development of clinical EAE and markedly decreased the extent 
of inflammatory infiltrates and demyelination of the optic nerve. Moreover, using a S. 
aureus strain deficient for the extracellular adherence protein we showed the beneficial 
effect of a chronic bacterial infection on disease modulating effect in EAE is due to the 
secretion of this protein. Furthermore, infection with S. aureus also increased the 
number of surviving RGCs and axonal counts that seems to be related to the anti-
inflammatory properties of Eap. Further studies are needed to clarify the direct 
neuroprotective effect of Eap. 
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